Values are typical for the standard grade. Tighter specifications are available — state the target in your inquiry and we confirm against the production batch.
L-Phenylalanine (CAS 63-91-2) is an essential amino acid widely used across industries such as food, pharmaceuticals, nutraceuticals, and animal nutrition. From a procurement perspective, it is valued for its high purity, stable chemical properties, and important role as a key building block in protein synthesis and metabolic processes.
Product Description
L-Phenylalanine (CAS 63-91-2) is an essential amino acid widely used across industries such as food and beverage, pharmaceuticals, nutraceuticals, and animal nutrition. From a procurement perspective, it is valued for its high purity, stable chemical characteristics, and its critical role as a precursor in protein synthesis and various metabolic pathways.
In food and beverage applications, L-Phenylalanine is commonly used as a nutritional fortifier and as a key component in the production of high-intensity sweeteners such as aspartame. Its consistent quality and stability enable manufacturers to maintain reliable taste profiles and product performance.
Within the nutraceutical and dietary supplement sector, L-Phenylalanine is utilized in formulations aimed at supporting cognitive function, mood balance, and overall metabolic health. Its compatibility with other amino acids and active ingredients allows for flexible formulation in capsules, tablets, and powder blends.
In pharmaceutical applications, L-Phenylalanine serves as an important intermediate and active component in specific therapeutic formulations. Its well-defined purity and controlled production standards are essential for meeting strict regulatory requirements.
In animal nutrition, L-Phenylalanine is used as a feed additive to improve protein utilization and support growth performance, contributing to more efficient feed formulations.
From a sourcing and supply chain standpoint, high-quality L-Phenylalanine provides:
High purity with strict impurity control
Stable chemical properties and long shelf life
Consistent batch-to-batch quality
Compliance with food grade and pharmaceutical grade standards
Flexible packaging options and reliable global supply
For buyers focused on product quality, formulation flexibility, and regulatory compliance, L-Phenylalanine is a reliable and versatile amino acid ingredient across multiple application sectors.
Delivery&Payment method
Frequently asked
Is a safety data sheet available for L-Phenylalanine?
Yes, on request. Safety data sheets are issued per grade and destination market; state the country of import in your inquiry.
What purity do you supply?
The standard grade is 99.5%. Tighter specifications are confirmed against the production batch before shipment.
3D-Modell L-Phenylalanine, CAS 63-91-2, Summenformel C9H11NO2, molare Masse 165.19 g/mol
Daten transkribiert aus regulatorischen Registern und Fachliteratur, unter Angabe von Quelle und Ausgabe. Sie ersetzen nicht das Sicherheitsdatenblatt des Lieferanten. Felder ohne hinterlegte Quelle sind als solche gekennzeichnet.
📊 Physikochemische Daten — CAS 63-91-2MolGod_PROPHUB_MAIN
📊Physikochemische Eigenschaften
Kurzübersicht
Formel:C9H11NO2
MW:165.19 g/mol
CAS:63-91-2
Aussehen:Prisms form water
Geruch:Slight
Detaillierte Eigenschaften
A supplement to the „Physicochemical properties (database)” table below — repeated values are shown only once.
PubChem. National Center for Biotechnology Information (NIH/NLM), chemical compound database. ↗
dotyczy: Schmelzpunkt · Siedepunkt · Wasserlöslichkeit · logP (Octanol/Wasser)
Václav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules2614
MOLECULE
Bibliografie pro CAS (live aus 13+ Datenbanken)
Quellen: db:pubmed (2) · db:doaj (1)
db:pubmed
Hedaya L, Naja K, Almuraikhy S et al.. (2025). "N-Lactoyl Phenylalanine Disrupts Insulin Signaling, Induces Inflammation, and Impairs Mitochondrial Respiration in Cell Models.". Cells. https://doi.org/10.3390/cells14161296 →
db:pubmed
Wobst HJ, Viader A, Muncipinto G et al.. (2024). "SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.". JCI insight. https://doi.org/10.1172/jci.insight.182876 →
db:doaj
Václav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules26144298 →
Regulatorischer Status der Substanz
Keine Einträge für diese CAS-Nummer in den geprüften Beschränkungslisten (SVHC-Kandidatenliste, REACH Anhang XVII; Datensätze unvollständig – dies ist keine Konformitätsbestätigung). CLP-Einstufung und Transportstatus (ADR): siehe Abschnitt GHS und Sicherheitsdatenblatt (SDS).
PubChem. National Center for Biotechnology Information (NIH/NLM), chemical compound database. ↗
dotyczy: PubChem CID · InChIKey · InChI · SMILES
ECHA. EC Inventory — EINECS, ELINCS, NLP and List Numbers assigned under REACH. Helsinki: European Chemicals Agency. ↗
dotyczy: EC Number
ChEMBL. European Bioinformatics Institute (EMBL-EBI), bioactivity database. ↗
dotyczy: ChEMBL
ChemSpider. Royal Society of Chemistry, chemical structure database. ↗
dotyczy: ChemSpider
Dalsza literatura
Publications thematically related to this CAS. They are not the source of any value given on this card.
Bibliografie (erweitert) (10)
★★★★★CANONICAL_PAPERS💰 Paywall (wahrsch.)✓ verifiziertJakka SR; Mugesh G. 2026. "p-Benzoyl-l-phenylalanine as a Multifunctional Noncanonical Amino Acid in Synthetic Biology: Photoprobing, Photocatalysis, and Structural Programming for Biocontainment." Angewandte Chemie (International ed. in English).Link[abgerufen: 2026-11-07]
★★★★★CANONICAL_PAPERS💰 Paywall (wahrsch.)✓ verifiziertZhang D; Liu B; Hu L et al.. 2023. "A novel L-phenylalanine dipeptide inhibits prostate cancer cell proliferation by targeting TNFSF9." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.Link[abgerufen: 2026-11-07]
★★★★½CANONICAL_PAPERS💰 Paywall (wahrsch.)✓ verifiziertMORRIS CJ; THOMPSON JF. 1962. "The isolation and characterization of gamma-L-glutamyl-L-tyrosine and gamma-L-glutamyl-L-phenylalanine from soybeans." Biochemistry.Link[abgerufen: 2026-11-07]
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertTanchai, Nipawan. "Improvement of the phenylalanine dehydrogenase immobilization method for the production of phenylalanine.". https://doi.org/10.58837/chula.the.2007.1012.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Self-Assembly of Phenylalanine-Leucine, Leucine-Phenylalanine and Cyclo(-leucine-phenylalanine) Dipeptides through Simulations and Experiments.". https://doi.org/10.1021/acs.jpcb.2c08576.s001.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine.". https://doi.org/10.31003/uspnf_m64020_04_01.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine Binding Is Linked to Dimerization of the Regulatory Domain of Phenylalanine Hydroxylase.". https://doi.org/10.1021/bi501109s.s001.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine.". https://doi.org/10.31003/uspnf_m64020_05_01.Link[abgerufen: 2026-11-07]CC0 (metadata)
★☆☆☆☆CANONICAL_PAPERS❓ ?✓ verifiziertEspinoza-González Á; Hernández-Valencia C; Cedeño-Caero L et al.. 2023. "Protease-catalyzed synthesis of α-poly-L-Lysine and amphiphilic poly(L-lysine-co-L-phenylalanine) in a neat non-toxic organic solvent." Bioprocess and biosystems engineering.Link[abgerufen: 2026-11-07]
★☆☆☆☆OPENLIBRARY🔓 OFFENMaria Yeng-Ying Kuo. 1977. "A kinetic study of the carboxypeptidase A catalyzed hydrolyses of Cinnamoylglycyl-L-phenylalanine (CinGP) and Hydrocinnamoylglycyl-L-phenylalanine (HCinGP) / by Maria Yeng-Ying Kuo." Miami University.Link[abgerufen: 2026-11-03]CC0 (metadata)
Spektren werden bei Bedarf aus 9 Quellen abgerufen. Jedes Spektrum wird in unserer Datenbank gespeichert — beim nächsten Öffnen erfolgt keine Anfrage an die externe API. Laden Sie JCAMP-DX / CSV / PNG zu jedem Spektrum herunter, ohne zu suchen.
Die Daten werden einmalig abgerufen (JCAMP-DX-Parser) und in der lokalen Datenbank des Plugins gespeichert. Keine doppelten Downloads, keine erneuten Anfragen an NIST bei späteren Aufrufen. Lizenzen werden eingehalten (veröffentlicht wird nur ein Deep-Link plus eigene Visualisierung).
Tabellierte Referenzwerte (1H und 13C) für CAS 63-91-2. Literaturquellen: Gottlieb 1997, Pretsch 2009, Silverstein 2014.
Referenzdaten aus der Literatur. Vor analytischer Verwendung mit einem Referenzspektrum verifizieren.
1H-NMR (DMSO-d6)
δ (ppm)
Multiplizität
Integration
J (Hz)
Zuordnung
8.06
br s
3
—
NH3+ (broad)
7.26
m
5
—
aromatic H-2,3,4,5,6
3.96
m
1
—
alpha-CH
3.02
dd
1
13.4
beta-CH2 (Ha)
2.73
dd
1
10.0
beta-CH2 (Hb)
Datenquelle: SDBS; Pretsch 2009
13C-NMR (DMSO-d6)
δ (ppm)
Multiplizität
Integration
J (Hz)
Zuordnung
170.40
s
—
—
COOH (C=O)
137.30
s
—
—
C-1 (ipso)
129.50
s
—
—
C-3,5 (meta)
128.80
s
—
—
C-2,6 (ortho)
127.10
s
—
—
C-4 (para)
54.00
s
—
—
alpha-C
36.50
s
—
—
beta-CH2
Datenquelle: SDBS; Pretsch 2009
Bibliografie (Chicago Author-Date)
Aue, W. P., E. Bartholdi, and R. R. Ernst. 1976. "Two-Dimensional Spectroscopy. Application to Nuclear Magnetic Resonance." Journal of Chemical Physics 64 (5): 2229–2246. [DOI]
Bodenhausen, Geoffrey, and D. J. Ruben. 1980. "Natural Abundance Nitrogen-15 NMR by Enhanced Heteronuclear Spectroscopy." Chemical Physics Letters 69 (1): 185–189.
Bax, Ad, and Donald G. Davis. 1985. "MLEV-17-Based Two-Dimensional Homonuclear Magnetization Transfer Spectroscopy." Journal of Magnetic Resonance 65 (2): 355–360.
Gottlieb, Hugo E., Vadim Kotlyar, and Abraham Nudelman. 1997. "NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities." Journal of Organic Chemistry 62 (21): 7512–7515. [DOI]
Harris, Robin K., Edwin D. Becker, Sonia M. Cabral de Menezes, Pierre Granger, Roy E. Hoffman, and Kurt W. Zilm. 2008. "Further Conventions for NMR Shielding and Chemical Shifts (IUPAC Recommendations 2008)." Pure and Applied Chemistry 80 (1): 59–84. [DOI]
Fulmer, Gregory R., Alexander J. M. Miller, Nathaniel H. Sherden, Hugo E. Gottlieb, Abraham Nudelman, Brian M. Rosen, Virgil Percec, and Paul J. Chirik. 2010. "NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities." Organometallics 29 (9): 2176–2179. [DOI]
Levitt, Malcolm H. 2008. Spin Dynamics: Basics of Nuclear Magnetic Resonance. 2nd ed. Chichester: Wiley. ISBN 978-0-470-51117-6
Friebolin, Horst. 2010. Basic One- and Two-Dimensional NMR Spectroscopy. 5th ed. Weinheim: Wiley-VCH. ISBN 978-3-527-32782-9
Berger, Stefan, and Siegmar Braun. 2004. 200 and More NMR Experiments: A Practical Course. Weinheim: Wiley-VCH. ISBN 978-3-527-31067-8
Sanders, Jeremy K. M., and Brian K. Hunter. 1993. Modern NMR Spectroscopy: A Guide for Chemists. 2nd ed. Oxford: Oxford University Press. ISBN 978-0-19-855514-8
Bovey, Frank A., and Peter A. Mirau. 1996. Nuclear Magnetic Resonance Spectroscopy. 2nd ed. San Diego: Academic Press. ISBN 978-0-12-119765-8
Becker, Edwin D. 2000. High Resolution NMR: Theory and Chemical Applications. 3rd ed. San Diego: Academic Press. ISBN 978-0-12-084660-9
Field, Leslie D., Sev Sternhell, and John R. Kalman. 2013. Organic Structures from Spectra. 5th ed. Chichester: Wiley. ISBN 978-1-118-32498-1
🔎 Spektrensuche (JCAMP-DX)
Laden Sie eine JCAMP-DX-Datei (.jdx, .dx, .jcm) hoch — das System berechnet die Cosine-Ähnlichkeit zu allen Spektren in der Datenbank und zeigt die TOP 10 Treffer an.
📚 Bibliografie (Chicago)
McLafferty, Fred W., ed. 2018. Wiley Registry of Mass Spectral Data. 11th ed. Hoboken, NJ: Wiley. Eine MS-Referenzbibliothek (~775k Spektren).
Stein, Stephen E., and Donald R. Scott. 1994. "Optimization and Testing of Mass Spectral Library Search Algorithms for Compound Identification." Journal of the American Society for Mass Spectrometry 5 (9): 859–866. Der Cosine- und Dot-Product-Algorithmus von NIST MS Search.
McDonald, Robert S., and Paul A. Wilks Jr. 1988. "JCAMP-DX: A Standard Form for Exchange of Infrared Spectra in Computer Readable Form." Applied Spectroscopy 42 (1): 151–162. Die JCAMP-DX-Spezifikation (erweitert auf 5.01 für NMR/MS).
McLafferty, Fred W., and František Tureček. 1993. "Interpretation of Mass Spectra." 4th ed. Mill Valley, CA: University Science Books. Cosine-Similarity-Matching und MS-Fragmentierung — die Grundlage des Suchalgorithmus.
Sumner, Lloyd W., Alexander Amberg, Dave Barrett, Michael H. Beale, Richard Beger, Clare A. Daykin, Teresa W.-M. Fan, et al. 2007. "Proposed Minimum Reporting Standards for Chemical Analysis." Metabolomics 3 (3): 211–221. MSI Level 1-4 — Standards für die Konfidenzstufe des spektralen Matchings.
Stein, Stephen E. 1999. "An Integrated Method for Spectrum Extraction and Compound Identification from Gas Chromatography/Mass Spectrometry Data." Journal of the American Society for Mass Spectrometry 10 (8): 770–781. Der AMDIS-Algorithmus — Dekonvolution + Library-Match (NIST).
Lindon, John C., George E. Tranter, and David W. Koppenaal, eds. 2017. "Encyclopedia of Spectroscopy and Spectrometry." 3rd ed. Amsterdam: Academic Press. Enzyklopädische Einträge zum Thema Spectral Library Searching.
Smith, Brian C. 2011. "Fundamentals of Fourier Transform Infrared Spectroscopy." 2nd ed. Boca Raton, FL: CRC Press. FT-IR und das JCAMP-DX-Format für Transmissionsspektren.
Larkin, Peter. 2017. "Infrared and Raman Spectroscopy: Principles and Spectral Interpretation." 2nd ed. Amsterdam: Elsevier. Grundlagen des IR/Raman-Library-Matchings und der Peak-Vorverarbeitung.
Strukturelle EigenschaftenMolGod_STRUCT3D_1
Strukturdaten werden geladen...
❓ Häufig gestellte Fragen (3)MolGod_FAQ_1
What is 63-91-2?
63-91-2 (CAS 63-91-2) is a chemical compound. The chemical data comes from PubChem (National Institutes of Health, USA).
Hilfreich?
What is the CAS number of 63-91-2?
The CAS number for 63-91-2 is 63-91-2. A CAS Registry Number is the standard identifier for a chemical substance in scientific literature and in trade.
Hilfreich?
How should 63-91-2 be stored?
63-91-2 should be stored as its safety data sheet directs \— typically in a dry, cool, well-ventilated place, away from heat and from materials it is incompatible with.
Hilfreich?
➕ Frage vorschlagen
Strukturdateien herunterladenMolGod_STRDL_1
Molekülstrukturdateien aus der PubChem-Datenbank (NIH). Kompatibel mit Avogadro, PyMOL, Jmol und ChemDraw.
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
g/L ↔ molarity
c (mol/L) = (g/L) / MW
±0.1% (depends on MW precision)
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
mmol/L ↔ molarity
c (mol/L) = mmol/L × 10⁻³
Exact
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
Celsius ↔ Kelvin
T(K) = t(°C) + 273.15
±0.01 K (ITS-90 scale)
BIPM (Bureau International des Poids et Mesures) (2019)
Celsius ↔ Fahrenheit
T(°F) = T(°C) × 9/5 + 32
±0.1 °F
Thompson A, Taylor BN (2008)
density-corrected % ↔ molarity
c (mol/L) = (%w/w × ρ × 10) / MW, ρ in g/mL
±0.1% when ρ known to 3 decimals
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
📚 Bibliographie (8 autoritative Quellen)
Thompson A, Taylor BN (2008). Guide for the Use of the International System of Units (SI). NIST Special Publication 811 · DOI: 10.6028/NIST.SP.811-2008 → Primary SI standard for US scientific usage
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007). Quantities, Units and Symbols in Physical Chemistry — The IUPAC Green Book. RSC Publishing, 3rd ed. · DOI: 10.1039/9781847557889 · ISBN: 978-0-85404-433-7 → Canonical IUPAC guide for chemistry quantities/units
BIPM (Bureau International des Poids et Mesures) (2019). The International System of Units (SI), 9th edition. BIPM · ↗ → International SI definitions (incl. redefined kilogram 2019)
ISO/IEC (2022). Quantities and units — Part 1: General. International Organization for Standardization — ISO 80000-1:2022 · ↗ → General rules for physical quantities and units
ISO/IEC (2019). Quantities and units — Part 9: Physical chemistry and molecular physics. International Organization for Standardization — ISO 80000-9:2019 · ↗ → Concentration / molality / amount-of-substance conventions
Tiesinga E, Mohr PJ, Newell DB, Taylor BN (2021). CODATA recommended values of the fundamental physical constants: 2018. Rev. Mod. Phys. 93(2):025010 · DOI: 10.1103/RevModPhys.93.025010 → Avogadro, gas constant, molar volume (2019 SI revision)
IUPAC (2019). Compendium of Chemical Terminology — the IUPAC Gold Book (online). IUPAC · DOI: 10.1351/goldbook → Definitions of mass fraction, molality, normality, ppm, activity
Mills IM, Cvitaš T, Homann K, Kallay N, Kuchitsu K (1988). Quantities, Units and Symbols in Physical Chemistry. Blackwell Scientific Publications, 1st ed. · ISBN: 0-632-01773-5 → Historical predecessor of IUPAC Green Book
Ähnliche MolekülstrukturenMolGod_SIMSTR_1
Ähnliche Strukturen werden geladen...
🧪 Assistent zur Lösungsvorbereitung WIZARDMolGod_PREP_1
Hinweis zu Datenbeschränkungen. Die Sicherheitsinformationen auf dieser Seite dienen nur zur Information und ersetzen kein vollständiges Sicherheitsdatenblatt (SDS). Konsultieren Sie vor der Verwendung des Produkts das aktuelle Sicherheitsdatenblatt des Herstellers sowie die GHS/CLP-Leitlinien. Die CLP-Einstufung bezieht sich auf die reine Bulk-Substanz, nicht auf handelsübliche Zubereitungen.
Keine harmonisierte GHS-Einstufung für diese Substanz — siehe aktuelles Sicherheitsdatenblatt (SDS) des Lieferanten.
☢️ Toxikologische Daten (IARC + EPA CTX)
🧬 IARC-Karzinogenitätseinstufung
IARC-Klassifizierung:
Kein individueller IARC-Eintrag für diese CAS
Keine eigene IARC-Monografie in den geprüften Verzeichnissen — dies ist KEINE Bestätigung für das Fehlen einer krebserzeugenden Wirkung. Prüfen Sie die CLP/GHS-Klassifizierung (Abschnitt CMR / GHS).
Hedaya L, Naja K, Almuraikhy S et al.. (2025). "N-Lactoyl Phenylalanine Disrupts Insulin Signaling, Induces Inflammation, and Impairs Mitochondrial Respiration in Cell Models.". Cells. https://doi.org/10.3390/cells14161296 [DOI]
Wobst HJ, Viader A, Muncipinto G et al.. (2024). "SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.". JCI insight. https://doi.org/10.1172/jci.insight.182876 [DOI]
Václav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules26144298 [DOI]
International Agency for Research on Cancer (IARC). 2024. "IARC Monographs on the Identification of Carcinogenic Hazards to Humans." Lyon: IARC. 🔗
U.S. EPA. 2024. "ECOTOX Knowledgebase." Washington, DC: U.S. Environmental Protection Agency. 🔗
ECHA. 2024. "Chemical Safety Assessment." European Chemicals Agency. 🔗
U.S. National Toxicology Program. 2024. Report on Carcinogens. 15th ed. Research Triangle Park, NC: National Institute of Environmental Health Sciences. 🔗
GESTIS. 2024. "GESTIS Substance Database." Institute for Occupational Safety and Health of the German Social Accident Insurance (DGUV). 🔗
U.S. EPA. 2024. "CompTox Chemicals Dashboard." Washington, DC: U.S. Environmental Protection Agency. 🔗
ECHA. 2023. "Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures (CLP), Annex VI — Harmonised Classification." European Chemicals Agency. 🔗
Leist, Marcel, et al. 2014. "Consensus Report on the Future of Animal-Free Systemic Toxicity Testing." ALTEX 31 (3): 341–356. [DOI]
Hartung, Thomas. 2009. "Toxicology for the Twenty-First Century." Nature 460 (7252): 208–212. [DOI]
Lenga, Robert E., ed. 2008. The Sigma-Aldrich Library of Chemical Safety Data. 2nd ed. Milwaukee: Sigma-Aldrich.
Slikker, William Jr., et al. 2004. "Dose-Dependent Terminal and Tissue Residues After Chronic Exposure." Toxicological Sciences 81 (2): 253–279. [DOI]
Calabrese, Edward J., and Linda A. Baldwin. 2003. "Toxicology Rethinks Its Central Belief." Nature 421 (6924): 691–692. [DOI]
ℹ️ Checkliste der regulatorischen Pflichten für CAS 63-91-2.
Status basierend auf: ADR 2025 (Tabelle A), REACH Anhang XVII, CLP Anhang VI (harmonisierte Einstufung), Gefahrenklasse aus der m14-spill-DB, SVHC, GIS und der polnischen NDS-Liste. Grundsatz: keine Daten = keine Aussage (wir erklären NICHT "keine Beschränkungen" ohne Grundlage).
✅SDS (Sicherheitsdatenblatt) verfügbarerfüllt
So gewährleisten Sie die Konformität: Anforderung: aktuelles SDB gemäß Verordnung 1907/2006 (REACH) Anhang II, 16-Abschnitte-Format.
Rechtsgrundlage: Regulation (EC) 1907/2006 (REACH) Art. 31 + Annex II
So gewährleisten Sie die Konformität: Brak potwierdzonej klasyfikacji dla tej substancji — obowiązku etykiety CLP NIE MOŻNA ORZEC. Nie zakładaj ani obowiązku, ani jego braku: zweryfikuj samoklasyfikację dostawcy oraz wpis w CLP zał. VI przed wprowadzeniem do obrotu.
So gewährleisten Sie die Konformität: Keine ADR-Daten im MOL-GOD-Datensatz für diese CAS-Nummer. Nehmen Sie NICHT an, dass keine Beschränkungen bestehen — überprüfen Sie vor dem Versand die Transporteinstufung in ADR 2025 (Tabelle A) und in Abschnitt 14 des Sicherheitsdatenblatts (SDS).
Rechtsgrundlage: European Agreement ADR 2025 + Act of 19 August 2011 on the transport of dangerous goods
So gewährleisten Sie die Konformität: Importeure/Hersteller ab ≥1 Tonne/Jahr müssen die Substanz bei der ECHA registrieren (technisches Dossier + Chemical Safety Report bei ≥10 t). Prüfen Sie die ECHA Annex VI / registered substances list.
So gewährleisten Sie die Konformität: SVHC-Status anhand des verfügbaren Datenbestands nicht überprüft — die aktuelle ECHA-Kandidatenliste prüfen; das Fehlen eines Eintrags nicht voraussetzen.
❓REACH Anhang XVII (Verwendungs-/Vermarktungsbeschränkungen)zu überprüfen
So gewährleisten Sie die Konformität: Brak wpisu w zbiorze klasyfikacji zharmonizowanej (CLP Załącznik VI) dla tego numeru CAS — status poz. 28–30 (zakaz CMR) NIEZWERYFIKOWANY; nie zakładać braku ograniczenia. Zbiór ograniczeń Załącznika XVII również niepełny — sprawdź skonsolidowany Załącznik XVII oraz klasyfikację zharmonizowaną CMR na stronach ECHA.
Rechtsgrundlage: Regulation (EC) 1907/2006 (REACH) Annex XVII — restrictions on manufacture/placing on the market/use
European Parliament and Council. 2008. Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures (CLP). Official Journal of the European Union L 353/1. CLP Regulation 1272/2008. [link ↗] — Einstufung, Kennzeichnung und Verpackung von Stoffen + Gemischen (GHS-Umsetzung in der EU)
European Parliament and Council. 2006. Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). Official Journal of the European Union L 396/1. REACH Regulation 1907/2006. [link ↗] — REACH — Registrierung, Bewertung und Zulassung von Chemikalien; SVHC; SDS Anhang II
Ministerstwo Rodziny i Polityki Społecznej Rzeczypospolitej Polskiej. 2024. Rozporządzenie Ministra Rodziny i Polityki Społecznej z dnia 4 września 2024 r. w sprawie najwyższych dopuszczalnych stężeń i natężeń czynników szkodliwych dla zdrowia w środowisku pracy. Dziennik Ustaw RP 2024 poz. 1017. [link ↗] — NDS und NDSCh für ~600 chemische Substanzen — aktuelle polnische Arbeitsplatzgrenzwerte
United Nations Economic Commission for Europe (UNECE). 2025. European Agreement concerning the International Carriage of Dangerous Goods by Road (ADR), 2025 Edition. United Nations, Geneva. ADR 2025. [link ↗] — Internationales Übereinkommen über den Straßentransport gefährlicher Güter — UN-Nummern, Klassen, Verpackungen
📚 Konsolidierte wissenschaftliche Referenzen — Chicago Author-Date 10 Quellen
Referenzen aus allen Safety-Hub-Registerkarten gesammelt. CAS: 63-91-2 ·
PubChem ↗
Parlament Europejski i Rada UE. 2008. "Rozporządzenie (WE) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji (CLP)." Dz.Urz. UE L 353. [↗]
GHS, Vorschriften
United Nations Economic Commission for Europe (UNECE). 2021. "Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Ninth Revised Edition." United Nations, Geneva. [↗]
GHS
Goldfrank, Lewis R., Robert S. Hoffman, Mary Ann Howland, et al.. 2019. "Goldfrank's Toxicologic Emergencies, 11th ed.." McGraw-Hill Education, New York. ISBN 978-1-25-985961-8.
Pierwsza pomoc, Toksykologia
National Institute for Occupational Safety and Health (NIOSH). 2023. "NIOSH Pocket Guide to Chemical Hazards (DHHS Publ. 2005-149)." U.S. Department of Health and Human Services / CDC, Cincinnati, OH. [↗]
Pierwsza pomoc, PPE, Toksykologia
European Committee for Standardization (CEN). 2016. "EN 374-1:2016 — Protective gloves against dangerous chemicals and micro-organisms." CEN, Brussels. [↗]
PPE
UNECE. 2023. "European Agreement Concerning the International Carriage of Dangerous Goods by Road (ADR 2025)." United Nations, Geneva. [↗]
Utylizacja, Regulacje
National Fire Protection Association (NFPA). 2022. "NFPA 400 — Hazardous Materials Code." NFPA, Quincy, MA. [↗]
Magazynowanie
Urben, P.G. (ed.). 2017. "Bretherick's Handbook of Reactive Chemical Hazards, 8th ed.." Butterworth-Heinemann / Elsevier, Oxford. [↗]
Magazynowanie
Ministerstwo Klimatu i Środowiska RP. 2023. "Baza danych o produktach i opakowaniach oraz o gospodarce odpadami (BDO)." Ministerstwo Klimatu i Środowiska, Warszawa. [↗]
Utylizacja
International Agency for Research on Cancer (IARC / WHO). 2024. "IARC Monographs on the Identification of Carcinogenic Hazards to Humans — List of Classifications." WHO, Lyon. [↗]
Toksykologia
Registerkarten mit eigenen Referenzen (Emergency, PPE, Storage, Waste) enthalten zusätzliche bibliografische Einträge in ihren jeweiligen Abschnitten.
📈Analytische Statistik (t-Test · RSD · Grubbs · Q-Dixon)ICH Q2
Fügen Sie eine Serie von Messwiederholungen ein (CSV oder eine Zahl pro Zeile). Der Rechner berechnet Mittelwert, Standardabweichung und 95% CI und erkennt Ausreißer (Grubbs + Dixon Q).
Trennzeichen: Komma, Leerzeichen, Tab, Zeilenumbruch. Min. 3 Messungen.
📐 Statistische Formeln
x̄ = Σxᵢ / n — arithmetisches Mittel
s² = Σ(xᵢ - x̄)² / (n-1) — Stichprobenvarianz
s = √s² — Standardabweichung
RSD% = (s / x̄) × 100% — relative Standardabweichung
Wählen Sie einen Puffer aus der Liste von 20 gängigen Systemen → geben Sie den Ziel-pH-Wert ein → Sie erhalten ein exaktes Rezept mit den einzuwiegenden Massen.
Schritt 1: Puffersystem wählen
Schritt 2: Pufferparameter
Schritt 3: Ihr Rezept
Schritt-für-Schritt-Verfahren:
📐 Berechnungsdetails (Henderson-Hasselbalch)
📜 Rezeptverlauf (letzte 10)
Pharmakologischer Status
Badania kliniczne Faza 3
Phase I
Phase II
Phase III
Zugelassen
Phase III — multizentrische Vergleichsstudien an einer großen Population.
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertTanchai, Nipawan. "Improvement of the phenylalanine dehydrogenase immobilization method for the production of phenylalanine.". https://doi.org/10.58837/chula.the.2007.1012.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Self-Assembly of Phenylalanine-Leucine, Leucine-Phenylalanine and Cyclo(-leucine-phenylalanine) Dipeptides through Simulations and Experiments.". https://doi.org/10.1021/acs.jpcb.2c08576.s001.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine.". https://doi.org/10.31003/uspnf_m64020_04_01.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine Binding Is Linked to Dimerization of the Regulatory Domain of Phenylalanine Hydroxylase.". https://doi.org/10.1021/bi501109s.s001.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine.". https://doi.org/10.31003/uspnf_m64020_05_01.Link[abgerufen: 2026-11-07]CC0 (metadata)
★☆☆☆☆OPENLIBRARY🔓 OFFENMaria Yeng-Ying Kuo. 1977. "A kinetic study of the carboxypeptidase A catalyzed hydrolyses of Cinnamoylglycyl-L-phenylalanine (CinGP) and Hydrocinnamoylglycyl-L-phenylalanine (HCinGP) / by Maria Yeng-Ying Kuo." Miami University.Link[abgerufen: 2026-11-03]CC0 (metadata)
📅Project Planner — Manager für LaborexperimenteNEU
Planen Sie Ihr gesamtes Laborprojekt: Fügen Sie Experimente mit Reagenzien, Wiederholungen und Dauer hinzu. Sie erhalten ein Gantt-Diagramm, eine Einkaufsliste (mit Links zum Shop!), ein Budget mit 10% Reserve und eine GHS-Risikomatrix.
💡 Melden Sie sich an, um Projekte zu speichern.
Ohne Anmeldung können Sie berechnen, aber nicht speichern.
🧪 Löslichkeit und Lösungsmittelkompatibilität MolGod_SOLUB_1
Molekül
L-Phenylalanine
Formel
C9H11NO2
logP (XLogP3)
-1.50
Masse (g/mol)
165.19
Polarität
Hydrophil (polar)
⚠️ GC-Schätzung (Hoftyzer–Van Krevelen). Keine HSP-Literaturdaten für diese CAS — Genauigkeit ±2 MPa½. Experimentell verifizieren.
Lösungsmittel
Compat.
Ra
Visuell
GC-MS
HPLC
Anwendungen
Referenzen
Ra < R₀ = good miscibility · Ra < 1,5×R₀ = borderline · above = poor (R₀ — radius of the Hansen sphere of this molecule) For this molecule R₀ = 8..
Löslichkeitstheorie (angewendet in der Verträglichkeitsvorhersage):
Yalkowsky, Samuel H., and Shri C. Valvani. 1980. "Solubility and Partitioning I: Solubility of Nonelectrolytes in Water." Journal of Pharmaceutical Sciences 69 (8): 912–922. https://doi.org/10.1002/jps.2600690814 — General Solubility Equation (GSE): logS = 0.5 − logP − 0.01(MP−25).
Hansen, Charles M. 2007. Hansen Solubility Parameters: A User's Handbook. 2nd ed. CRC Press. https://doi.org/10.1201/9781420006834 — HSP-Triplett (dD, dP, dH) + Ra-Formel.
Stefanis, E., and C. Panayiotou. 2008. "Prediction of Hansen Solubility Parameters with a New Group-Contribution Method." Int J Thermophys 29: 568–585. https://doi.org/10.1007/s10765-008-0415-z
Reichardt, Christian, and Thomas Welton. 2011. Solvents and Solvent Effects in Organic Chemistry. 4th ed. Wiley-VCH. https://doi.org/10.1002/9783527632220 — E_T(30) polarity scale, solwatochromia.
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. Introduction to Modern Liquid Chromatography. 3rd ed. Wiley. https://doi.org/10.1002/9780470508183 — Eluotropic series, polarity index.
Van Krevelen, D. W., and K. Te Nijenhuis. 2009. Properties of Polymers. 4th ed. Elsevier. https://doi.org/10.1016/B978-0-08-054819-7.X0001-5 — Hoftyzer–Van Krevelen group contribution dla dD/dP/dH z SMILES.
Marcus, Yizhak. 1998. The Properties of Solvents. Wiley Series in Solution Chemistry, Vol. 4. ISBN 9780471983699 — Vollständige tabellarische Sammlung von 250+ Lösungsmitteln (ε, μ, Donizität, Akzeptorzahlen).
PubChem Compound Database — CAS 63-91-2 lookup ↗ — logP (XLogP3), water solubility experimental + predicted.
Vollständige Bibliografie im Akkordeon REFERENZEN (am Ende der Seite) — Chicago Manual of Style 17th ed., Author-Date.
🧮 Löslichkeitsrechner
Löslichkeit:—
logS:—
Methode:—
⚠️ —
Löslichkeit vs. Temperatur
🌐 Hansen Solubility Sphere (3D)
⚠️ The Hansen parameters for this substance fall outside the range of the method.
At least one of the δD/δP/δH parameters fell outside the domain of validity of the group contribution method (Hoftyzer–Van Krevelen), so the position of the molecule in Hansen space is unknown. The distance Ra is measured FROM THAT POINT — it cannot be calculated without knowing the point. The sphere and the distance table have been omitted rather than filled with numbers that have nothing behind them. Where a solubility measurement exists, it is shown in the table below.
Drug-Likeness-Radardiagramm (Lipinski Ro5 / Veber). Grüne Zone = Übereinstimmung mit den Kriterien.
Vorhersagedaten — in silico berechnete Eigenschaften (SMILES/RDKit). Sie ersetzen keine klinischen Studien. Nicht zur Arzneimittelbewertung ohne experimentelle Verifizierung verwenden.
Lipinski, Christopher A., Franco Lombardo, Beryl W. Dominy, and Paul J. Feeney. 1997. "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings." Advanced Drug Delivery Reviews 23 (1-3): 3-25.
Veber, Daniel F., Stephen R. Johnson, Hung-Yuan Cheng, et al. 2002. "Molecular properties that influence the oral bioavailability of drug candidates." Journal of Medicinal Chemistry 45 (12): 2615-2623.
Daina, Antoine, Olivier Michielin, and Vincent Zoete. 2017. "SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness." Scientific Reports 7: 42717.
Egan, William J., and Gregory Lauri. 2002. "Prediction of intestinal permeability." Advanced Drug Delivery Reviews 54 (3): 273-289.
Baell, Jonathan B., and Georgina A. Holloway. 2010. "New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries." Journal of Medicinal Chemistry 53 (7): 2719-2740.
Brenk, Ruth, Alessandro Schipani, Daniel James, et al. 2008. "Lessons learnt from assembling screening libraries for drug discovery for neglected diseases." ChemMedChem 3 (3): 435-444.
Ertl, Peter, and Ansgar Schuffenhauer. 2009. "Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions." Journal of Cheminformatics 1: 8.
Bickerton, G. Richard, Gaia V. Paolini, Jérémy Besnard, Sorel Muresan, and Andrew L. Hopkins. 2012. "Quantifying the Chemical Beauty of Drugs." Nature Chemistry 4 (2): 90-98.
Hopkins, Andrew L., and Colin R. Groom. 2002. "The Druggable Genome." Nature Reviews Drug Discovery 1 (9): 727-730.
Ghose, Arup K., Vellarkad N. Viswanadhan, and John J. Wendoloski. 1999. "A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery." Journal of Combinatorial Chemistry 1 (1): 55-68.
Tice, Raymond R., Christopher P. Austin, Robert J. Kavlock, and John R. Bucher. 2013. "Improving the Human Hazard Characterization of Chemicals: A Tox21 Update." Environmental Health Perspectives 121 (7): 756-765.
Leeson, Paul D., and Brian Springthorpe. 2007. "The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry." Nature Reviews Drug Discovery 6 (11): 881-890.
Hann, Michael M. 2011. "Molecular Obesity, Potency and Other Addictions in Drug Discovery." MedChemComm 2 (5): 349-355.
Davies, Mark, Michał Nowotka, George Papadatos, et al. 2015. "ChEMBL Web Services: Streamlining Access to Drug Discovery Data and Utilities." Nucleic Acids Research 43 (W1): W612-W620.
Walters, W. Patrick, and Mark A. Murcko. 2002. "Prediction of 'Drug-Likeness.'". Advanced Drug Delivery Reviews 54 (3): 255–271. https://doi.org/10.1016/S0169-409X(02)00003-0.
Congreve, Miles, Robin Carr, Christopher Murray, and Harren Jhoti. 2003. "A 'Rule of Three' for Fragment-Based Lead Discovery?" Drug Discovery Today 8 (19): 876–877. https://doi.org/10.1016/S1359-6446(03)02831-9.
Brenk, Ruth, Alessandro Schipani, Daniel James, Agata Krasowski, Iain Hugh Gilbert, Julie Frearson, and Paul Graham Wyatt. 2008. "Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases." ChemMedChem 3 (3): 435-444.
Schomburg, Karen T., Sascha Bietz, Hans Briem, Andrea M. Henzler, Stefan Urbaczek, and Matthias Rarey. 2014. "Facing the Challenges of Structure-Based Target Prediction by Inverse Virtual Screening." Journal of Chemical Information and Modeling 54 (6): 1676-1686.
Bemis, Guy W., and Mark A. Murcko. 1996. "The Properties of Known Drugs. 1. Molecular Frameworks." Journal of Medicinal Chemistry 39 (15): 2887-2893.
Schomburg, Karen T., and Matthias Rarey. 2014. "What Is the Potential of Structure-Based Target Prediction Methods?" Future Medicinal Chemistry 6 (17): 1987-1989.
Hedaya L, Naja K, Almuraikhy S et al.. (2025). "N-Lactoyl Phenylalanine Disrupts Insulin Signaling, Induces Inflammation, and Impairs Mitochondrial Respiration in Cell Models.". Cells. https://doi.org/10.3390/cells14161296
Wobst HJ, Viader A, Muncipinto G et al.. (2024). "SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.". JCI insight. https://doi.org/10.1172/jci.insight.182876
Václav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules26144298
Tanchai, Nipawan. "Improvement of the phenylalanine dehydrogenase immobilization method for the production of phenylalanine.". https://doi.org/10.58837/chula.the.2007.1012. [DOI ↗]
Anonymous. "Self-Assembly of Phenylalanine-Leucine, Leucine-Phenylalanine and Cyclo(-leucine-phenylalanine) Dipeptides through Simulations and Experiments.". https://doi.org/10.1021/acs.jpcb.2c08576.s001. [DOI ↗]
Anonymous. "Phenylalanine Binding Is Linked to Dimerization of the Regulatory Domain of Phenylalanine Hydroxylase.". https://doi.org/10.1021/bi501109s.s001. [DOI ↗]
Maria Yeng-Ying Kuo. 1977. "A kinetic study of the carboxypeptidase A catalyzed hydrolyses of Cinnamoylglycyl-L-phenylalanine (CinGP) and Hydrocinnamoylglycyl-L-phenylalanine (HCinGP) / by Maria Yeng-Ying Kuo." Miami University. ↗
Bolton, Evan E., Yanli Wang, Paul A. Thiessen, and Stephen H. Bryant. 2008. "PubChem: Integrated Platform of Small Molecules and Biological Activities." Annual Reports in Computational Chemistry 4: 217-241. [DOI ↗]
Kim, Sunghwan, Jie Chen, Tiejun Cheng, et al. 2023. "PubChem 2023 update." Nucleic Acids Research 51 (D1): D1373-D1380. [DOI ↗]
Kim, Sunghwan, Tiejun Cheng, Jianyong He, Chen Cheng, et al. 2021. "PubChem Protein, Pathway, Reaction, and Disease Specifications." Journal of Cheminformatics 13: 16. [DOI ↗]
Hähnke, Volker D., Sunghwan Kim, and Evan E. Bolton. 2018. "PubChem chemical structure standardization." Journal of Cheminformatics 10: 36. [DOI ↗]
Wang, Yanli, Stephen H. Bryant, Tiejun Cheng, Jiyao Wang, et al. 2017. "PubChem BioAssay: 2017 update." Nucleic Acids Research 45 (D1): D955-D963. [DOI ↗]
Cheng, Tiejun, et al. 2014. "Computation of Octanol-Water Partition Coefficients by Guiding an Additive Model with Knowledge." Journal of Chemical Information and Modeling 54 (3): 793-805. [DOI ↗]
Wilkinson, Mark D., et al. 2016. "The FAIR Guiding Principles for scientific data management and stewardship." Scientific Data 3: 160018. [DOI ↗]
Hersey, Anne, et al. 2015. "Chemical databases: curation or integration by user-defined equivalence?" Drug Discovery Today: Technologies 14: 17-24.
Sandra Lynn Elliott. 2001. "Enzyme-mediated degradation of L-phenylalanine based segmented polyurethaneureas." National Library of Canada. ↗
Veber, Daniel F., Stephen R. Johnson, Hung-Yuan Cheng, Brian R. Smith, Keith W. Ward, and Kenneth D. Kopple. 2002. "Molecular Properties That Influence the Oral Bioavailability of Drug Candidates." Journal of Medicinal Chemistry 45 (12): 2615-2623.
ECHA. 2024. "REACH Guidance." European Chemicals Agency. ↗
Groom, Colin R., Ian J. Bruno, Matthew P. Lightfoot, and Suzanna C. Ward. 2016. "The Cambridge Structural Database." Acta Crystallographica Section B 72 (2): 171-179. ↗
🧪Assistent zur Lösungsherstellung (Smart Prep)MolGod_PREP_2
Geben Sie ein, was Sie zubereiten möchten — ich erstelle eine SOP
Beispiele unten — zum Einfügen anklicken:
Fertige Rezepte:
📚 Überblick über die wissenschaftliche Literatur — CAS 63-91-2MolGod_LITHUB_MAIN
📊 Automatisch extrahierte Themen aus den Abstracts von 1 Publikationen für CAS 63-91-2.
Algorithmus: TF-IDF (Salton & Buckley 1988) — Termfrequenz × inverse Dokumentfrequenz.
📊 Graf citations für CAS 63-91-2.
Jeder Knoten = eine wissenschaftliche Arbeit; eine A→B-Kante = Arbeit A zitiert B. Daten von OpenAlex (Priem 2022).
⚡ Netzwerkdaten abrufen
Das Netzwerk wird bei Bedarf aus der OpenAlex-API aufgebaut (24-h-Cache).
🔬 HPLC — Methoden und Parameter — CAS 63-91-2MolGod_HPLCHUB_MAIN
🔬 HPLC/GC-Methoden (2 Methoden)
📄
Insight Into the Metabolomic Characteristics of Post-Transplant Diabetes Mellitus by the Integrated LC-MS and GC-MS Approach- Preliminary Study
UHPLCFrontiers in Endocrinology202293% ✓CC-BYResearch method (specificity, robustness)
Säule: C18, 100 x 2.1 mm, 2.6 μm
Phase: consisting of acetonitrile (mobile phase A) and 0.1% formic acid (mobile phase…
Detektion: MS
Fluss: 0.40 mL/min
Temp.: 80.0 °C
Inj.: 5 μL
Gradient: elution involved a mobile phase consisting of acetonitrile (mobile phase…
Wang M, Xu J, Yang N, Zhang T, Zhu H, Wang J. Insight Into the Metabolomic Characteristics of Post-Transplant Diabetes Mellitus by the Integrated LC-MS and GC-MS Approach- Preliminary Study. Frontiers in Endocrinology. 2022;12:807318. doi:10.3389/fendo.2021.807318
Post-transplantation diabetes mellitus (PTDM) is a common metabolic complication after solid organ transplantation, which not only results in elevated microvascular morbidity, but also seriously impacts graft function and recipient survival. However, its underlying mechanism is not yet fully understood. In this study, an integrated liquid chromatography- mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) based-metabolomics approach was adopted to dissect the metabolic fluctuations and deduce potential mechanism associated with PTDM. 68 adult liver transplant recipients were recruited and classified as 32 PTDM and 36 non-PTDM subjects. PTDM group and non-PTDM group were well matched in gender, age, BMI, family history of diabetes, alcohol drinking history, ICU length of stay and hepatitis B infection. Peripheral blood samples from these recipients were collected and prepared for instrument analysis. Data acquired from LC-MS and GC-MS demonstrated significant metabolome alterations between PTDM and non-PTDM subjects. A total of 30 differential metabolites (15 from LC-MS, 15 from GC-MS) were screened out. PTDM patients, compared with non-PTDM subjects, were characterized with increased levels of L-leucine, L-phenylalanine, LysoPE (16:0), LysoPE (18:0), LysoPC (18:0), taurocholic acid, glycocholic acid, taurochenodeoxycholic acid, tauroursodeoxycholic acid, glycochenodeoxycholic acid, glycoursodeoxycholic acid, etc, and with decreased levels of LysoPC (16:1), LysoPC (18:2), LysoPE (22:6), LysoPC (20:4), etc. Taken collectively, this study demonstrated altered metabolites in patients with PTDM, which would provide support for enhancing mechanism exploration, prediction and treatment of PTDM.
Serum Metabolomics Study of Papillary Thyroid Carcinoma Based on HPLC-Q-TOF-MS/MS
HPLCFrontiers in Cell and Developmental202186% ✓CC-BYResearch method (specificity)
Säule: C18, 100 x 2.1 mm, 2.2 μm
Phase: A was 0.1% (volume fraction) formic acid/water, and mobile phase B was…
Detektion: MS/MS
Temp.: 80.0 °C
Gradient: was set as follows: 2% B for 0–2 min, 50%…
Du Y, Fan P, Zou L, Jiang Y, Gu X, Yu J, et al. Serum Metabolomics Study of Papillary Thyroid Carcinoma Based on HPLC-Q-TOF-MS/MS. Frontiers in Cell and Developmental Biology. 2021;9:593510. doi:10.3389/fcell.2021.593510
This study examined metabolite profile differences between serum samples of thyroid papillary carcinoma (PTC) patients and healthy controls, aiming to identify candidate biomarkers and pathogenesis pathways in this cancer type. Serum samples were collected from PTC patients (n = 80) and healthy controls (n = 80). Using principal component analysis (PCA), partial least squares discrimination analysis(PLS-DA), orthogonal partial least square discriminant analysis (OPLS-DA), t-tests, and the volcano plot, a model of abnormal metabolic pathways in PTC was constructed. PCA, PLS-DA, and OPLS-DA analysis revealed differences in serum metabolic profiles between the PTC and control group. OPLS-Loading plot analysis, combined with Variable importance in the projection (VIP)>1, Fold change (FC) > 1.5, and p < 0.05 were used to screen 64 candidate metabolites. Among them, 22 metabolites, including proline betaine, taurocholic acid, L-phenylalanine, retinyl beta-glucuronide, alpha-tocotrienol, and threonine acid were upregulated in the PTC group; meanwhile, L-tyrosine, L-tryptophan, 2-arachidonylglycerol, citric acid, and other 42 metabolites were downregulated in this group. There were eight abnormal metabolic pathways related to the differential metabolites, which may be involved in the pathophysiology of PTC. Six metabolites yielded an area under the receiver operating curve of >0.75, specifically, 3-hydroxy-cis-5-tetradecenoylcarnitine, aspartylphenylalanine, l-kynurenine, methylmalonic acid, phenylalanylphenylalanine, and l-glutamic acid. The Warburg effect was observed in PTC. The levels of 3-hydroxy-cis-5-tetradecenoylcarnitine, aspartylphenylalanine, l-kynurenine, methylmalonic acid, phenylalanine, and L-glutamic acid may help distinguish PTC patients from healthy controls. Aspartic acid metabolism, glutamic acid metabolism, urea cycle, and tricarboxylic acid cycle are involved in the mechanism of PTC.
Snyder, Lloyd R., John W. Dolan, and Joseph J. Kirkland. 2010. Introduction to Modern Liquid Chromatography. Wiley. — Chapter 9 — gradient elution, LSS theory (cited as Snyder et al. 2010 in tool description).
Schoenmakers, Peter J. 1986. Optimization of Chromatographic Selectivity: A Guide to Method Development. Elsevier. — Numerical optimization of gradient programs.
Snyder, L. R., and J. W. Dolan. 2007. High-Performance Gradient Elution: The Practical Application of the Linear-Solvent-Strength Model. Wiley. — Foundational LSS reference for the %B_init = 5 + 8·logP heuristic implemented here.
Nikitas, Pavlos, and Adrian Pappa-Louisi. 2009. "Retention models for isocratic and gradient elution in reversed-phase liquid chromatography." Journal of Chromatography A 1216: 1737-1755. [DOI ↗] — Modern review of gradient retention models — basis for non-LSS extensions.
Carr, Peter W.. 2009. "The new physical chemistry of HPLC." Journal of Chromatography A 1216: 1764-1772. [DOI ↗]
Dong, Michael W. 2019. HPLC and UHPLC for Practicing Scientists. Wiley. https://doi.org/10.1002/9781119313793. — Modern UHPLC gradient programming, sub-2 µm scaling rules.
Wu, Naijun, and Anton M. Clausen. 2007. "Fundamental and practical aspects of ultrahigh pressure liquid chromatography for fast separations." Journal of Separation Science 30: 1167-1182. [DOI ↗]
Stoll, Dwight R., and Peter W. Carr. 2017. "Two-Dimensional Liquid Chromatography: A State of the Art Tutorial." Analytical Chemistry 89: 519-531. [DOI ↗] — Reference for orthogonal gradient design (2D-LC second dimension).
Dolan, John W.. 2013. "When to Modify Method Conditions." LCGC North America 31: 192-199.
Meyer, Veronika R. 2010. Practical High-Performance Liquid Chromatography. Wiley. — Chapter 7 — practical gradient design with isokratyczny scouting.
REST: /wp-json/molgod/v1/hplc/gradient/63-91-2
📐 Säulenabmessungen — van-Deemter-RechnerN=12,466
Formel: H = A + B/u + C·u (Van Deemter et al. 1956), N = L/H, ΔP ≈ η·L·u / (K_p·dp²) (Knox 1977). u_opt = √(B/C) (Giddings 1965).
Van Deemter, J. J., F. J. Zuiderweg, and A. Klinkenberg. 1956. "Longitudinal diffusion and resistance to mass transfer as causes of nonideality in chromatography." Chemical Engineering Science 5: 271-289. https://doi.org/10.1016/0009-2509(56)80003-1 — Original van Deemter equation paper — basis of H = A + B/u + C·u in this calculator.
Giddings, J. Calvin. 1965. "Dynamics of Chromatography, Part I: Principles and Theory.". Marcel Dekker. — Theoretical underpinning of HETP minimum and u_opt = sqrt(B/C).
Poppe, Hans. 1997. "Some reflections on speed and efficiency of modern chromatographic methods." Journal of Chromatography A 778: 3-21. https://doi.org/10.1016/S0021-9673(97)00376-2 — Speed-efficiency Pareto plot — context for sub-2 µm UHPLC scaling.
Wu, Naijun, and Anton M. Clausen. 2007. "Fundamental and practical aspects of ultrahigh pressure liquid chromatography for fast separations." Journal of Separation Science 30: 1167-1182. https://doi.org/10.1002/jssc.200700026 — UHPLC pressure scaling — extends Darcy ΔP formula to sub-2 µm particles.
Carr, Peter W.. 2009. "The new physical chemistry of HPLC." Journal of Chromatography A 1216: 1764-1772. https://doi.org/10.1016/j.chroma.2008.11.094 — Modern reinterpretation of A, B, C terms (eddy diffusion vs. b-term).
Knox, John H.. 1977. "Practical aspects of LC theory." Journal of Chromatographic Science 15: 352-364. https://doi.org/10.1093/chromsci/15.9.352 — Reduced plate height equation h = a·v^(1/3) + b/v + c·v.
Dong, Michael W.. 2019. "HPLC and UHPLC for Practicing Scientists.". Wiley (2nd ed.). https://doi.org/10.1002/9781119313793 — Practical N targets vs particle size table (UHPLC method scaling).
Snyder, L. R., J. J. Kirkland, and J. L. Glajch. 1997. "Practical HPLC Method Development.". Wiley (2nd ed.). — Column dimensioning rules of thumb (L, dp, dc) for given α and N.
Engelhardt, Heinz. 2014. "100 Years of Chromatography.". Wiley-VCH (2nd ed.).
Sadek, Paul C.. 2002. "The HPLC Solvent Guide.". Wiley-Interscience (2nd ed.).
Snyder, L. R.. 1978. "Classification of the solvent properties of common liquids." Journal of Chromatographic Science 16: 223-234. https://doi.org/10.1093/chromsci/16.6.223
Reichardt, Christian, and Thomas Welton. 2010. "Solvents and Solvent Effects in Organic Chemistry.". Wiley-VCH (4th ed.).
Vailaya, Anant, and Csaba Horváth. 1998. "Retention thermodynamics in hydrophobic interaction chromatography." Industrial & Engineering Chemistry Research 37: 4040-4055. https://doi.org/10.1021/ie980212h
Krstulović, Andrea M., and Phyllis R. Brown. 1981. "Reversed-phase High-Performance Liquid Chromatography.". Wiley.
Snyder, L. R., J. J. Kirkland, and J. L. Glajch. 1997. "Practical HPLC Method Development.". Wiley (2nd ed.).
Carr, Peter W.. 2009. "The new physical chemistry of HPLC." Journal of Chromatography A 1216: 1764-1772. https://doi.org/10.1016/j.chroma.2008.11.094
Boysen, Reinhard I., and Milton T. W. Hearn. 2009. "Multi-modal HPLC of proteins." Journal of Chromatographic Science 47: 645-654. https://doi.org/10.1093/chromsci/47.8.645
Dong, Michael W.. 2019. "HPLC and UHPLC for Practicing Scientists.". Wiley (2nd ed.). https://doi.org/10.1002/9781119313793
Skoog, Douglas A., F. James Holler, and Stanley R. Crouch. 2017. "Principles of Instrumental Analysis." 7th ed. Cengage Learning. ISBN 978-1-305-57721-3.
Perkampus, Heinz-Helmut. 1992. "UV-VIS Spectroscopy and Its Applications." Springer. ISBN 978-3-642-77479-9. →
Sadek, Paul C.. 2002. "The HPLC Solvent Guide." 2nd ed. Wiley-Interscience. ISBN 978-0-471-41138-4.
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. "Introduction to Modern Liquid Chromatography." 3rd ed. Wiley. ISBN 978-0-470-16754-0. →
Dong, Michael W.. 2019. "HPLC and UHPLC for Practicing Scientists." 2nd ed. Wiley. ISBN 978-1-119-31378-3. →
Stoll, Dwight R., and Peter W. Carr. 2017. "Two-Dimensional Liquid Chromatography: A State of the Art Tutorial." Analytical Chemistry 89: 519-531 →
Vivó-Truyols, Gabriel, and Hans-Gerd Janssen. 2010. "Probabilistic approach to peak deconvolution in chromatography." Analytical Chemistry 82: 8525-8531 →
Kazakevich, Yuri V., and Rosario LoBrutto, eds.. 2007. "HPLC for Pharmaceutical Scientists." Wiley-Interscience. ISBN 978-0-471-68162-4. →
Kim, Sunghwan, et al.. 2023. "PubChem 2023 update." Nucleic Acids Research 51: D1373-D1380 →
MOLECULE
Bibliografie pro CAS (live aus 13+ Datenbanken)
Quellen: db:pubmed (2) · db:doaj (1)
db:pubmed
Hedaya L, Naja K, Almuraikhy S et al.. (2025). "N-Lactoyl Phenylalanine Disrupts Insulin Signaling, Induces Inflammation, and Impairs Mitochondrial Respiration in Cell Models.". Cells. https://doi.org/10.3390/cells14161296 →
db:pubmed
Wobst HJ, Viader A, Muncipinto G et al.. (2024). "SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.". JCI insight. https://doi.org/10.1172/jci.insight.182876 →
db:doaj
Václav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules26144298 →
REST: /wp-json/molgod/v1/hplc/detector/63-91-2
🧪 Systemeignung — Live-Rechner (USP <621>)
Geben Sie Daten aus 5-6 Injektionen ein (Flächen, tR, Tailing, Böden) — der Rechner berechnet %RSD, Mittelwerte und prüft die Konformität mit USP <621>. Sie können CSV (kommagetrennt) einfügen oder einzelne Werte bearbeiten.
📚 Referenzen (Chicago Author-Date)
USP General Chapter <621>. 2024. "Chromatography (System Suitability section)." USP-NF 2024 ed. United States Pharmacopeial Convention. [link ↗] — Defines RSD area < 2%, tailing < 2.0, N > 2000 acceptance criteria.
International Council for Harmonisation (ICH). 2023. "Validation of Analytical Procedures Q2(R2)." ICH Expert Working Group. [link ↗] — Section 5.4 — system suitability is part of method validation.
US Food and Drug Administration (FDA). 2018. "Reviewer Guidance: Validation of Chromatographic Methods." US Food and Drug Administration. [link ↗] — CDER reviewer perspective on chromatographic validation expectations.
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. "Introduction to Modern Liquid Chromatography." 3rd ed. Wiley. — Chapter 2 — system suitability fundamentals (RSD, Tf, N).
Heyden, Yvan Vander, et al.. 2009. "Robustness of pharmaceutical liquid chromatographic methods." — Robustness vs. system suitability — design-of-experiments framework.
Rozet, Eric, et al.. 2013. "Analysis of recent pharmaceutical regulatory documents on analytical method validation."
European Medicines Agency (EMA). 2011. "Guideline on bioanalytical method validation EMEA/CHMP/EWP/192217/2009." EMA. [link ↗] — EMA companion guideline with bioanalytical SS criteria.
Dong, Michael W.. 2019. "HPLC and UHPLC for Practicing Scientists." 2nd ed. Wiley. — UHPLC-specific suitability adjustments (n=5 vs. n=6).
Kazakevich, Yuri V., and Rosario LoBrutto, eds.. 2007. "HPLC for Pharmaceutical Scientists." Wiley-Interscience.
AOAC International. 2016. "Appendix F: Guidelines for Standard Method Performance Requirements." AOAC INTERNATIONAL. [link ↗] — Alternative SS thresholds for food/dietary samples.
📊 HPLC-Methodenvalidierung (ICH Q2(R1))PARTIAL
3 of 3 critical metrics need experimental data
Parameter
Wert
Einheit
ICH-Q2-Kriterium
Status
Linearität (R²)
keine Daten
unitless
R² ≥ 0.999 (≥0.99 für bioanalytische)
—
LOD (S/N = 3:1)
keine Daten
ng/mL
S/N ≥ 3:1 (niedrigste nachweisbare Konzentration)
—
LOQ (S/N = 10:1)
keine Daten
ng/mL
S/N ≥ 10:1 (LOQ ≥ 3×LOD typischerweise)
—
Präzision (RSD intraday, n=6)
keine Daten
% RSD
RSD ≤ 2% (intraday) / ≤ 3% (interday) für den API
—
Richtigkeit (Wiederfindung, 3 Niveaus)
keine Daten
% (target 100±2%)
Recovery 98-102% (target 100%)
—
Linearitätsbereich
keine Daten
z. B. 0.1-100 ng/mL
Mind. 80-120% der Nominalkonzentration
—
Selektivität/Spezifität
keine Daten
qualitative
Keine Interferenz — Analyt-Peak vollständig aufgelöst (Rs ≥ 2.0)
—
Robustheit (Robustness)
keine Daten
RSD < 2% bei ±5% Variation
RSD < 2% bei kleinen Parametervariationen
—
Legende:✓ PASS⚠ CAUTION✗ FAIL— NO_DATA
📚 Wissenschaftliche Referenzen (Chicago Author-Date) — zum Aufklappen klicken
Standards für die Validierung analytischer Methoden — 4 unabhängige Quellen (ICH + USP + AOAC + Snyder).
International Conference on Harmonisation (ICH). 2005. Validation of Analytical Procedures: Text and Methodology Q2(R1). ICH Expert Working Group. [link ↗] — Gold-standard ICH guideline — accepted by EMA, FDA, MHLW, NMPA
United States Pharmacopeia (USP) Convention. 2024. USP General Chapter <621> Chromatography. USP-NF 2024 ed. USP. [link ↗]
AOAC International. 2016. Appendix F: Guidelines for Standard Method Performance Requirements. AOAC INTERNATIONAL. [link ↗] — AOAC SMPR — alternative to ICH Q2 for food/dietary supplements
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. Introduction to Modern Liquid Chromatography. 3rd ed. John Wiley & Sons. ISBN 978-0-470-16754-0. https://doi.org/10.1002/9780470508183 [link ↗] — Industry standard textbook — Chapter 11 covers method validation
Snyder, L. R., J. J. Kirkland, and J. L. Glajch. 1997. Practical HPLC Method Development. 2nd ed. Wiley. ISBN 978-0-471-00703-6. — Classic method-development reference (DryLab heritage).
Rozet, Eric, et al.. 2013. Analysis of recent pharmaceutical regulatory documents on analytical method validation. https://doi.org/10.1016/j.chroma.2007.03.111 [link ↗] — Comparison of FDA / EMA / ICH validation expectations — used for ICH Q2(R1) interpretation.
Heyden, Yvan Vander, et al.. 2009. Robustness of pharmaceutical liquid chromatographic methods. https://doi.org/10.1016/j.jchromb.2008.10.052 [link ↗] — Plackett-Burman design for robustness — basis of ICH Q2 §3.7.
Dong, Michael W.. 2019. HPLC and UHPLC for Practicing Scientists. 2nd ed. Wiley. ISBN 978-1-119-31378-3. https://doi.org/10.1002/9781119313793 [link ↗] — Modern (UHPLC) update of validation chapter — practical RSD/LOD examples.
Meyer, Veronika R.. 2010. Practical High-Performance Liquid Chromatography. 5th ed. Wiley. ISBN 978-0-470-68218-0. — European pharmacopeial perspective — complements USP/AOAC.
Kazakevich, Yuri V., and Rosario LoBrutto, eds.. 2007. HPLC for Pharmaceutical Scientists. Wiley-Interscience. ISBN 978-0-471-68162-4. https://doi.org/10.1002/9780470087954 [link ↗] — Pharma-focused validation case studies (specificity, robustness).
European Medicines Agency (EMA). 2011. Guideline on bioanalytical method validation EMEA/CHMP/EWP/192217/2009. EMA Committee for Medicinal Products for Human Use. [link ↗] — EMA bioanalytical companion to ICH Q2(R1) for clinical samples.
Berechnen Sie den USP-Tailing-Faktor (T) und die Asymmetrie (As) aus den Peak-Halbwertsbreiten. Geben Sie a (linke Halbbreite) und b (rechte Halbbreite) an, gemessen bei 5% oder 10% der Peakhöhe.
📚 Referenzen (Chicago Author-Date)
USP General Chapter <621>. 2024. "Chromatography." United States Pharmacopeial Convention. [link ↗] — Defines USP Tailing Factor T = (a+b)/(2a) measured at 5% peak height.
International Council for Harmonisation (ICH). 2023. "Validation of Analytical Procedures Q2(R2)." ICH Expert Working Group. [link ↗] — Tailing factor is a system suitability parameter (Section 6).
Foley, Joe P., and John G. Dorsey. 1983. "Equations for calculation of chromatographic figures of merit for ideal and skewed peaks." Analytical Chemistry 55: 730-737 https://doi.org/10.1021/ac00255a033 [link ↗] — Original asymmetry factor As = b/a at 10% height (Foley & Dorsey 1983).
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. "Introduction to Modern Liquid Chromatography." Wiley. https://doi.org/10.1002/9780470508183 [link ↗] — Chapter 2.4 — peak shape diagnostics and remedies.
Dolan, John W.. 2003. "Peak tailing and resolution." LCGC North America 21: 610-614 [link ↗] — How tailing factor degrades effective resolution.
Vivó-Truyols, Gabriel, and Hans-Gerd Janssen. 2010. "Probabilistic approach to peak deconvolution in chromatography." Analytical Chemistry 82: 8525-8531 https://doi.org/10.1021/ac101742z [link ↗] — Modern numerical deconvolution for asymmetric peaks.
Kromidas, Stavros. 2017. "HPLC Made to Measure: A Practical Handbook for Optimization." Wiley-VCH. — Practical Tf and As thresholds for routine QC.
Dong, Michael W.. 2019. "HPLC and UHPLC for Practicing Scientists." Wiley. https://doi.org/10.1002/9781119313793 [link ↗]
Heyden, Yvan Vander, et al.. 2009. "Robustness of pharmaceutical liquid chromatographic methods." Journal of Chromatography B 877: 2120-2129 https://doi.org/10.1016/j.jchromb.2008.10.052 [link ↗]
📊 Rechner für Auflösung und Bodenzahl (Rs, N, H)
Berechnen Sie die Auflösung Rs, die theoretische Bodenzahl N und HETP (H) für ein Paar von HPLC-Peaks. Geben Sie die Retentionszeiten, Peakbreiten (bei 50% oder an der Basis) und die Säulenlänge an.
📚 Referenzen (Chicago Author-Date)
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. "Introduction to Modern Liquid Chromatography." 3rd ed. John Wiley & Sons. ISBN 978-0-470-16754-0. https://doi.org/10.1002/9780470508183 [link ↗] — Chapter 2 covers resolution, plate count and HETP fundamentals (Snyder et al. 2010).
USP General Chapter <621>. 2024. "Chromatography." USP-NF 2024 ed. United States Pharmacopeial Convention. [link ↗] — Defines Rs >= 1.5 acceptance criterion and N calculation methods.
Dolan, John W.. 2003. "How much resolution is enough?." LCGC North America 21: 350-353 [link ↗] — Practical guidance on Rs targets for routine method development.
Van Deemter, J. J., F. J. Zuiderweg, and A. Klinkenberg. 1956. "Longitudinal diffusion and resistance to mass transfer as causes of nonideality in chromatography." Chemical Engineering Science 5: 271-289 https://doi.org/10.1016/0009-2509(56)80003-1 [link ↗] — Origin of N = 5.54·(tr/w0.5)² half-height plate count formulation.
Giddings, J. Calvin. 1965. "Dynamics of Chromatography, Part I: Principles and Theory." Marcel Dekker. ISBN 978-0-8247-1357-7. — Resolution equation Rs = (1/4)·√N·(α-1)/α·k/(1+k) (master equation).
Foley, Joe P., and John G. Dorsey. 1983. "Equations for calculation of chromatographic figures of merit for ideal and skewed peaks." Analytical Chemistry 55: 730-737 https://doi.org/10.1021/ac00255a033 [link ↗] — Skewed-peak corrections to apparent N.
Knox, John H.. 1977. "Practical aspects of LC theory." Journal of Chromatographic Science 15: 352-364 https://doi.org/10.1093/chromsci/15.9.352 [link ↗]
Carr, Peter W.. 2009. "The new physical chemistry of HPLC." Journal of Chromatography A 1216: 1764-1772 https://doi.org/10.1016/j.chroma.2008.11.094 [link ↗]
Dong, Michael W.. 2019. "HPLC and UHPLC for Practicing Scientists." 2nd ed. Wiley. ISBN 978-1-119-31378-3. https://doi.org/10.1002/9781119313793 [link ↗]
🔧 Fehlerbehebung HPLC — Entscheidungsbaum6 häufige Probleme
Diagnose der 6 häufigsten HPLC-Probleme mit Entscheidungsbaum (5 Schritte pro Problem). Quelle: Snyder/Kirkland/Dolan 3rd ed. Chapter 17 + LCGC LC Troubleshooting columns 1989-2024.
Verbreiterte Peaks (broad peaks) medium
Symptom: Alle Peaks im Chromatogramm sind breiter als erwartet (FWHM > 2× normal)
🔍 Diagnosebaum:
1. Prüfen Sie, ob alle Peaks verbreitert sind oder nur einige → JA: Alle → instrumentelles Problem (Säule oder System) → NEIN: Nur einige → chemisches Problem (Wechselwirkung mit der Säule bei bestimmten Analyten)
2. Tauschen Sie eine Testsäule ein — verschwindet das Problem? → JA: SÄULE verschlissen — Packung beschädigt, Void in den ersten mm. Ersetzen. → NEIN: Problem im LC-System
3. Prüfen Sie das Totvolumen (dead volume) — Injektionsschleife, Verbindungen, Detektor → JA: Schleife > 100 µL für eine 4.6-mm-Säule oder lose Verbindungen → Ferrulen ersetzen, Kapillaren kürzen → NEIN: Diagnose fortsetzen
4. Temperaturtest: Erhöhen Sie die Säule von 25°C auf 40°C → JA: Schmalere Peaks → Massentransferkinetik zu langsam (T erhöhen) → NEIN: Continue
5. Prüfen Sie die Flussrate gegenüber dem van-Deemter-Optimum für diese Säule → JA: Optimum für 4.6mm/5µm = 1.0 mL/min, für 2.1mm/3µm = 0.4 mL/min → NEIN: Continue
⚠️ Typische Ursachen:
Säule verschlissen (>2000 Injektionen ohne Vorsäule)
Totvolumen des Systems > 100 µL (falsche Schleife, lange Kapillaren, lose Ferrulen)
Temperatur zu niedrig (Massentransferkinetik)
Flussrate außerhalb des van-Deemter-Optimums
Probenlösungsmittel stärker als mobile Phase A
✓ Lösungen:
✓ Säule ersetzen (bei >2000 Injektionen)
✓ Alle Verbindungen prüfen — Kapillaren so kurz wie möglich
✓ Säulentemperatur auf 40°C erhöhen (wenn die Substanz stabil ist)
✓ Fluss auf das van-Deemter-Optimum reduzieren
✓ Probe in mobiler Phase A lösen (nicht in reinem Organischem)
Peak-Tailing (Tailing, T > 1.5) high
Symptom: Peaks haben einen verlängerten "Schwanz" auf der Seite der späten Elution (Asymmetrie T = b/a > 1.5 gemäß USP)
🔍 Diagnosebaum:
1. Enthält die Substanz basische Gruppen (Amino, Pyridin)? → JA: Ja → Silanol-Wechselwirkungen! Fügen Sie 0.1% TFA oder 5-10 mM TEA zur mobilen Phase A hinzu. → NEIN: Continue
2. Prüfen Sie den pH der mobilen Phase gegenüber dem pKa der Substanz → JA: pH = pKa ± 1 → teilweise Ionisierung, Peak-Split. Gehen Sie pH ≥ 2 Einheiten vom pKa weg. → NEIN: Continue
3. Prüfen Sie das Alter der Säule (>1500 Injektionen?) → JA: Ja → freigelegte Silanole (Column Bleed). Ersetzen Sie die Säule durch eine mit höherem Endcapping (XTerra, Symmetry). → NEIN: Continue
4. Enthält die Probe Metalle (Fe, Cu aus Glasfläschchen)? → JA: Ja → verwenden Sie klare Typ-II-Fläschchen oder PFA. 0.1mM EDTA zur Probe geben. → NEIN: Continue
⚠️ Typische Ursachen:
Silanol-Wechselwirkungen (basischer Analyt + freie Silanole des Kieselgels)
pH an der Grenze des Analyt-pKa (Peak-Split)
Alte Säule (Column Bleed, hohe Silanolaktivität)
Metalle in der Probe (Chelatbildung → Tailing)
Säulenüberladung (>50 µg auf einer 4.6mm-Säule)
✓ Lösungen:
✓ 0.1% TFA (UV) oder 0.1% Ameisensäure (LC-MS) zur mobilen Phase A hinzufügen
✓ Wählen Sie eine Säule mit hochreinem Endcapping: Waters XBridge BEH, Phenomenex Kinetex
✓ Arbeiten Sie bei pH ≥ 2 Einheiten vom pKa entfernt
✓ 0.1mM EDTA zur Probe (Fe/Cu-Chelatbildung)
✓ Injektionsvolumen auf ≤ 20 µL für eine 4.6mm-Säule reduzieren
Grundliniendrift (Baseline Drift) medium
Symptom: Die Grundlinie steigt oder fällt systematisch über >5 Minuten
🔍 Diagnosebaum:
1. Verwenden Sie einen Gradienten (B% steigt)? → JA: Ja → unterschiedliche Absorption der Phasen A vs. B bei dλ. Lösungsmittelwechsel im UV-Cutoff. Prüfen Sie die UV-Absorption des %-Organik-Anteils. → NEIN: Weiter (isokratisch)
2. Prüfen Sie die Säulentemperatur — ist sie auf ±0.5°C stabil? → JA: Ja (stabil) → weiter → NEIN: Instabil → Säulenthermostat einschalten (>25°C kontrolliert)
Symptom: Der erwartete Analyt-Peak erscheint nicht im Chromatogramm
🔍 Diagnosebaum:
1. Hat die Injektion tatsächlich stattgefunden? → JA: Prüfen Sie das Autosampler-Log, den Pumpendruck (sollte bei der Injektion abfallen) → NEIN: Autosampler-Problem → Schleife, Nadel, Probe im Fläschchen prüfen
2. Ist die Probe im Fläschchen (korrektes Volumen, nicht verdunstet)? → JA: Continue → NEIN: Keine Probe — erneut pipettieren
3. Probenstabilität — vor >24h vorbereitet? → JA: Ja → Degradation. Bereiten Sie eine frische Probe vor. → NEIN: Continue
4. Prüfen Sie die Detektionswellenlänge gegenüber dem λmax der Substanz → JA: Detektion bei λ entspricht NICHT dem λmax → kein Signal. DAD 200-400nm scannen. → NEIN: Continue
5. Test: Injizieren Sie einen reinen Standard (bekannter Konzentration, frisch) → JA: Standard ergibt einen Peak → Problem mit der Probe (Matrix, Derivatisierung) → NEIN: Kein Peak auch mit dem Standard → Systemproblem (Säule, Phase, Gradient)
⚠️ Typische Ursachen:
Probe nicht aus dem Fläschchen entnommen (Autosampler-Fehler)
Probe degradiert (>24h pH/Temp/Licht)
Detektion bei falscher Wellenlänge
Falsche mobile Phase (z. B. vergessenes TFA)
Säule umgekehrt / falsche stationäre Phase
Substanz eluiert an der Front (V0) → nicht retendiert, nicht sichtbar
✓ Lösungen:
✓ Frische Probe nach dem exakten Protokoll neu vorbereiten
✓ UV-Vis-DAD-Scan 200-400nm + Suche nach λmax
✓ Zusammensetzung der mobilen Phase prüfen — TFA hinzugefügt?
✓ Umgekehrte Säulenrichtung testen (vorsichtig!)
✓ Bei Retention <1 min — % B verringern, MeOH statt ACN
✓ Prüfen Sie die erwartete Retentionszeit in der Methodendatenbank des Plugins
Druck zu hoch (pressure too high) critical
Symptom: Pumpendruck > 80% des Säulenmaximums oder System-Shutdown mit High-Pressure-Fehler
🔍 Diagnosebaum:
1. Prüfen Sie, ob die Säule korrekt angeschlossen ist (Pfeilrichtung) → JA: OK → NEIN: Säule umgekehrt → umdrehen (niemals "rückwärts" betreiben)
2. Test: Säule aus dem System entfernen, nur Pumpe+Detektor betreiben → JA: Druck fällt auf <50 bar → Problem in der Säule (verstopft) → NEIN: Druck bleibt hoch → In-Line-Filter verstopft, Fritte verschmutzt
3. Prüfen Sie den Vorsäulenfilter (In-Line-Fritte) → JA: Verschmutzt und braun → ersetzen → NEIN: Continue
4. Säule rückwärts mit 50:50 ACN:H2O spülen, ohne die Säule — verschwindet es? → JA: Partikel im ersten mm stecken geblieben — 30 min Spülung kann sie wiederherstellen → NEIN: Säule ersetzen
⚠️ Typische Ursachen:
In-Line-Filter (Fritte) mit Partikeln verstopft
Puffer-Aussalzung (Ausfällung bei hohem %B)
Probe enthält Schwebstoffe (0.22 µm vor der Injektion filtrieren)
Säule verstopft (Column Bed Compaction)
Gradient mit Pufferphase + viel Organik → Salzausfällung
✓ Lösungen:
✓ Probe IMMER durch 0.22 µm PVDF vor der Injektion filtrieren
✓ In-Line-Filter alle 100 Injektionen ersetzen (oder wenn der Druck >20% steigt)
✓ Verwenden Sie NICHT >20mM Phosphatpuffer + >70% ACN (das Salz fällt aus)
✓ Säule 30 min mit 50:50 ACN:H2O in umgekehrter Richtung spülen (wenn vom Hersteller zugelassen)
✓ Vorsäule 4×3mm zum Schutz der Hauptsäule
Geisterpeaks (Ghost Peaks) high
Symptom: Unerklärte Peaks im Chromatogramm, die in der Kalibrierung fehlen
🔍 Diagnosebaum:
1. Test: Blindinjektion (reines Probenlösungsmittel) → JA: Ein Geisterpeak erscheint → Kontamination des Systems oder der Eluenten → NEIN: Erscheint nur mit der Probe → Matrix
2. Wächst der Geisterpeak mit dem Gradienten (eluiert bei hohem %B)? → JA: Ja → überladene Säule oder stark retendiert aus einem vorherigen Lauf → NEIN: Unabhängig vom Gradienten → Autosampler-Verschleppung
3. Increase carryover wash (between injections) → JA: Hilft → Verschleppung war die Ursache. Stärkeres Waschprotokoll. → NEIN: Continue
4. Reinwasser-Injektion — gibt es einen Peak? → JA: Ja → Kontamination der Wasserquelle (Organik aus dem DI-System) → NEIN: Continue
⚠️ Typische Ursachen:
Verschleppung in Autosampler-Nadel/-Schleife
Eluent-Kontamination (auch in HPLC-Qualität)
Stark retendierte Komponenten aus vorherigen Läufen
Kunststoff in den Fläschchen (Phthalate, PEG aus den Kappen)
DI-Wasser unzureichend gereinigt
✓ Lösungen:
✓ Waschprotokoll verstärken: 100% B → 100% A → 50:50 (3 Zyklen)
✓ Starke Wäsche: 100% DMSO oder 100% MeOH vor der Kalibrierung
✓ Eluenten im Zweifelsfall durch 0.22 µm PTFE filtrieren
✓ Braunglas + Teflon-beschichtete Kappen für Proben verwenden
✓ Periodische Gradientenrampe auf 100% B für 10 min (Reinigung)
📚 Wissenschaftliche Referenzen (Chicago Author-Date) — zum Aufklappen klicken
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. Introduction to Modern Liquid Chromatography. 3rd ed. John Wiley & Sons. Chapter 17 (Troubleshooting) pp. 559-616. ISBN 978-0-470-16754-0. https://doi.org/10.1002/9780470508183 [link ↗]
Dolan, John W.. 2014. LC Troubleshooting (monthly column 1989-2024). LCGC North America. [link ↗] — John Dolan 35-letnia seria miesięcznych artykułów problemowych
Kromidas, Stavros. 2017. HPLC Made to Measure: A Practical Handbook for Optimization. 2nd ed. Wiley-VCH. ISBN 978-3-527-31377-1. — Praktyczny przewodnik problem-solving dla labs analitycznych
Dolan, John W.. 2013. When to Modify Method Conditions. 192-199. [link ↗] — Decision flow for changing flow rate / temperature / %B vs swapping columns.
Dong, Michael W.. 2019. HPLC and UHPLC for Practicing Scientists. 2nd ed. Wiley. ISBN 978-1-119-31378-3. https://doi.org/10.1002/9781119313793 [link ↗] — Chapter 9 covers troubleshooting modern UHPLC systems (sub-2 µm particles).
Snyder, L. R., J. J. Kirkland, and J. L. Glajch. 1997. Practical HPLC Method Development. 2nd ed. Wiley. ISBN 978-0-471-00703-6. — Method-development companion volume with troubleshooting cross-refs.
Carr, Peter W.. 2009. The new physical chemistry of HPLC. 1764-1772. https://doi.org/10.1016/j.chroma.2008.11.094 [link ↗] — Theoretical basis for diagnosing efficiency losses (mass-transfer, eddy diffusion).
Heyden, Yvan Vander, et al.. 2009. Robustness of pharmaceutical liquid chromatographic methods. 2120-2129. https://doi.org/10.1016/j.jchromb.2008.10.052 [link ↗] — How to diagnose method failures vs. system failures (Plackett-Burman).
Engelhardt, Heinz. 2014. 100 Years of Chromatography. 2nd ed. Wiley-VCH. ISBN 978-3-527-33473-5. — Historical context for ghost-peak phenomenology (silica chemistry).
Molekülspezifische Szenarien, Fehlerbehebung und Literaturhinweise
📈 Molecular Predictor
The predicted parameters for this molecule (CAS 63-91-2) are based on literature-backed models (Snyder-Dolan LSS, Neue pore-size rules).
⏱️Retention Time
-2.55 min
Range: 0.5 – -3.32
confidence: medium
Model: Snyder-Dolan LSS na kolumnie C18 150×4.6 mm, gradient 5→95% B w 15 min
👁️UV λmax
254 nm
confidence: medium
Aromatic ring detected → 254 nm optimal
🧪Concentration
0.5 mg/mL
= 3.027 mM
confidence: high
Safe linear range detektora UV (nie przekroczy 1.5 AU)
⚗️Buffer pH
2
Range: 1.5 – 2.5
confidence: medium
Acid (pKa=0) → mobile phase pH 2 keeps the neutral form (better peak shape)
💉Injection Volume
20 μL
confidence: medium
Smaller volume for larger molecules (avoiding peak broadening)
⚠️ Predykcje oparte na modelach chemometrycznych — require validation against an actual measurement. Confidence: low/medium/high depending on the available descriptors.
⚠ Echtes Chemiker-Problem
Pressure too high — what next?
Pressure rises to 400 bar (max 300 for this column). The system is blaring an alarm. Do you shut the pump down? Yes/no?
Dla logP=-1.5 rekomendacja zależy: jeśli logP<2 (polarny) → MeOH retencja wystarczy; logP≥2 (niepolarny) → ACN daje lepszy peak shape. Dla tej molekuły (MW=165.19, CAS 63-91-2) zaczynaj od ACN w gradiencie 5→95% B.
Pracujesz na analitycznym Agilent 1100 (max 400 bar). Czy zamiana na 2.7 μm core-shell da rzeczywisty benefit?
✅ Our Gradient Strategy
Initial hold 0–2 min @ 5% B — sample adsorbs on the head
Ramp 2–15 min do 95% B — linear, curve 6 (Empower)
Final hold 15–20 min @ 95% B — elute strongly retained
Re-equilibrate 20–23 min back to 5% B + 5 col.volumes
🔧 Gradient Visualizer
Gradient Timeline
#
Time
%B start
%B end
Duration
Slope (Δ%B/min)
Step
Slope & Dwell Volume Test
—
Slope (Δ%B/min)
—
Gradient volume (mL)
—
Dwell vol estimate (mL)
—
k*·t0 (dla Rs)
💡 Rule of thumb: slope 2-5 %B/min gives the best peak shape · dwell vol = empty tubing from the pump to the column (check a blank run without the column) · k*·t0 ≥ 3 dla Rs ≥ 2.0.
📚 Snyder-Dolan LSS Model
Log k = log kw − S·φ, gdzie φ = fraction B. Optymalny gradient: Δφ ≈ 0.6–0.8 per 5 t0. Dla kolumny 250×4.6mm @ 1 mL/min → t0 ≈ 2 min → gradient 10–12 min.
❓ Häufig gestellte Fragen
Heurystyka Snydera: start%B = (logP - 1) × 10. Dla logP=2 → start 10% B. Zawsze z 2 min isocratic hold aby pozwolić próbce zaadsorbować.
Heurystyka Snyder: Rt ≈ 2.5·logP + 1.2 min. Dla (2S)-2-amino-3-phenylpropanoic acid (logP=-1.5) → szacunkowe Rt=-2.55 min. ±30% wariancja zależnie od dead volume i gradient slope. Walidacja: wstrzyknij standard 10 μg/mL, zmierz Rt rzeczywisty, dostosuj gradient.
Mała kolumnka (2cm) PRZED główną. Łapie zanieczyszczenia. Koszt 200 PLN, wymiana co 100 wstrzyknięć. Oszczędność: 1600 PLN na lifetime głównej kolumny.
Dla API (active pharmaceutical ingredient) typowo 98-102% label claim. Dla (2S)-2-amino-3-phenylpropanoic acid (CAS 63-91-2) sprawdź: (1) USP monograph jeśli istnieje, (2) kompendium pharmacopoeia wewnętrzna, (3) ICH Q6A dla specyfikacji nowych substancji. Related substances ≤0.10% per ICH Q3A.
Echte Pannen von Chemikern — was passiert ist, was geholfen hat und was zu vermeiden ist.
Ghost peaks w ostatnim dniu stability
Dr. Tomasz W., PhD pharmaceutical2024-08-22Poziom 4/5
Was ist passiert:
Day 90 stability pull. 6 batch × 2 repeats. W próbce widzę duplikaty peaków z poprzedniego dnia. OOS opened. 4 dni investigation. Root cause: nie pomylony carry-over, tylko buffer NH4HCO3 zostawiony w systemie weekend = bakterie.
💡 Lekcja:
NIGDY nie zostawiaj buforu w systemie >3 dni. Zawsze flush z 80% ACN/20% H2O przed weekendem. Koszt lekcji: 4 dni pracy + 3 batch release delay.
Why am I not seeing any peaks?
Student MSc, UW2024-10Poziom 2/5
Was ist passiert:
You injected the sample, you wait 23 min and... a flat line. Anxiety is rising.
💡 Lekcja:
Wavelength 254 nm does not work for most carboxylic acids — use 210 nm.
🤖 Ask about this method
Hallo — ich bin auf alle Szenarien, FAQ und Literatur zu dieser Methode trainiert. Fragen Sie mich alles.
👥 Share your scenario
Do you have experience with this method? A problem you solved? A mishap you want to spare others? Write to us — after moderator approval it will appear here as „real case".
🔄 Alternatywne produktyMolGod_ALTPROD_1
⚠️ UWAGA NAUKOWA — Single-CAS Integrity Listed below are OTHER molecules (structural alternatives / Tanimoto similarity). All physicochemical values (MW, pKa, LD50, GHS, spectra) apply to THESE alternatives, NOT the current molecule (CAS 63-91-2). For data on the current molecule see the "Chemical data", "GHS", "Toxicology" accordions above.
⚗️ Jonizacja w funkcji pH (Henderson-Hasselbalch)MolGod_PHION_1
Typ: Amfoteryczny · pKa: 2.2 · pKa2: 9.31
pH
% jonowy
% niejonowy
0
99.4 %
0.6 %
2
61.3 %
38.7 %
4
1.6 %
98.4 %
6
0.1 %
99.9 %
8
4.7 %
95.3 %
10
83.0 %
17.0 %
12
99.8 %
0.2 %
14
100.0 %
0.0 %
Sources for this substance (12)
CRC Handbook 91st ed. Lide, David R., ed. 2010. CRC Handbook of Chemistry and Physics. 91st ed. Boca Raton, FL: CRC Press.
CRC Handbook 105th ed. Rumble, John R., Thomas J. Bruno, Maria J. Doa, and Donald R. Burgess, eds. 2024. CRC Handbook of Chemistry and Physics. 105th ed. Boca Raton, FL: CRC Press.
NIST WebBook — link Linstrom, Peter J., and William G. Mallard, eds. 2024. NIST Chemistry WebBook. NIST Standard Reference Database Number 69. Gaithersburg, MD: National Institute of Standards and Technology.
PubChem CID 6140 — link Kim, Sunghwan, Jie Chen, Tiejun Cheng, Asta Gindulyte, Jia He, Siqian He, Qingliang Li, et al. 2023. "PubChem 2023 update." Nucleic Acids Research 51 (D1): D1373-D1380. PubChem CID 6140.
DrugBank DB00120 — link Knox, Craig, Mike Wilson, Christen M. Klinger, Mark Franklin, Eponine Oler, Alex Wilson, Allison Pon, et al. 2024. "DrugBank 6.0: the DrugBank Knowledgebase for 2024." Nucleic Acids Research 52 (D1): D1265-D1275. DrugBank ID DB00120.
ChEMBL CHEMBL301523 — link Zdrazil, Barbara, Eloy Felix, Fiona Hunter, Emma J. Manners, James Blackshaw, Sybilla Corbett, Marleen de Veij, et al. 2024. "The ChEMBL Database in 2023." Nucleic Acids Research 52 (D1): D1180-D1192. ChEMBL ID CHEMBL301523.
KEGG COMPOUND C00079 — link Kanehisa, Minoru, Miho Furumichi, Yoko Sato, Masayuki Kawashima, and Mari Ishiguro-Watanabe. 2023. "KEGG for taxonomy-based analysis of pathways and genomes." Nucleic Acids Research 51 (D1): D587-D592.
IUPAC Serjeant, E. P., and Boyd Dempsey. 1979. Ionisation Constants of Organic Acids in Aqueous Solution. IUPAC Chemical Data Series No. 23. Oxford: Pergamon Press.
IUPAC Perrin, Douglas D. 1965. Dissociation Constants of Organic Bases in Aqueous Solution. IUPAC. London: Butterworths.
NIST Goldberg, Robert N., Nand Kishore, and Rebecca Lennen. 2002. "Thermodynamic Quantities for the Ionization Reactions of Buffers." Journal of Physical and Chemical Reference Data 31 (2): 231-370.
Textbook Nelson, David L., and Michael M. Cox. 2017. Lehninger Principles of Biochemistry. 7th ed. New York: W. H. Freeman.
Bibliografia metody (Chicago)
Henderson, L. J. 1908. "Concerning the Relationship between the Strength of Acids and Their Capacity to Preserve Neutrality." American Journal of Physiology 21 (4): 173-179.
Hasselbalch, K. A. 1917. "Die Berechnung der Wasserstoffzahl des Blutes aus der freien und gebundenen Kohlensäure desselben." Biochemische Zeitschrift 78: 112-144.
Po, Henry N., and N. M. Senozan. 2001. "The Henderson-Hasselbalch Equation: Its History and Limitations." Journal of Chemical Education 78 (11): 1499-1503.
Avdeef, Alex. 2012. "Absorption and Drug Development: Solubility, Permeability, and Charge State." 2nd ed. Wiley.
Avdeef, Alex. 2007. "Solubility of sparingly-soluble ionizable drugs." Advanced Drug Delivery Reviews 59 (7): 568-590.
Volgyi, Gergely, et al. 2007. "Potentiometric and spectrophotometric pKa determination of water-insoluble compounds." Analytica Chimica Acta 583 (2): 418-428.
Fini, Adamo, Giuseppe Fazio, and Giuseppina Feroci. 1997. "Solubility and solubilization properties of non-steroidal anti-inflammatory drugs." Pharmaceutica Acta Helvetiae 70 (4): 305-318.
Mauger, John W., Anthony N. Paruta, and Robert J. Gerraughty. 1972. "Solubilities of sulfadiazine, sulfisomidine, and sulfadimethoxine." Journal of Pharmaceutical Sciences 61 (1): 94-97.
Lyman, Warren J., William F. Reehl, and David H. Rosenblatt. 1990. "Handbook of Chemical Property Estimation Methods." American Chemical Society.
Marcus, Yizhak. 1998. "The Properties of Solvents." Wiley.
Serjeant, E. P., and Boyd Dempsey. 1979. Ionisation Constants of Organic Acids in Aqueous Solution. IUPAC Chemical Data Series No. 23. Oxford: Pergamon Press.
Perrin, Douglas D. 1965. Dissociation Constants of Organic Bases in Aqueous Solution. IUPAC. London: Butterworths.
Goldberg, Robert N., Nand Kishore, and Rebecca Lennen. 2002. "Thermodynamic Quantities for the Ionization Reactions of Buffers." Journal of Physical and Chemical Reference Data 31 (2): 231-370.
Rumble, John R., Thomas J. Bruno, Maria J. Doa, and Donald R. Burgess, eds. 2024. CRC Handbook of Chemistry and Physics. 105th ed. Boca Raton, FL: CRC Press.
Lide, David R., ed. 2010. CRC Handbook of Chemistry and Physics. 91st ed. Boca Raton, FL: CRC Press.
Kim, Sunghwan, Jie Chen, Tiejun Cheng, Asta Gindulyte, Jia He, Siqian He, Qingliang Li, et al. 2023. "PubChem 2023 update." Nucleic Acids Research 51 (D1): D1373-D1380.
Knox, Craig, Mike Wilson, Christen M. Klinger, Mark Franklin, Eponine Oler, Alex Wilson, Allison Pon, et al. 2024. "DrugBank 6.0: the DrugBank Knowledgebase for 2024." Nucleic Acids Research 52 (D1): D1265-D1275.
Zdrazil, Barbara, Eloy Felix, Fiona Hunter, Emma J. Manners, James Blackshaw, Sybilla Corbett, Marleen de Veij, et al. 2024. "The ChEMBL Database in 2023." Nucleic Acids Research 52 (D1): D1180-D1192.
Kanehisa, Minoru, Miho Furumichi, Yoko Sato, Masayuki Kawashima, and Mari Ishiguro-Watanabe. 2023. "KEGG for taxonomy-based analysis of pathways and genomes." Nucleic Acids Research 51 (D1): D587-D592.
Linstrom, Peter J., and William G. Mallard, eds. 2024. NIST Chemistry WebBook. NIST Standard Reference Database Number 69. Gaithersburg, MD: National Institute of Standards and Technology.
Nelson, David L., and Michael M. Cox. 2017. Lehninger Principles of Biochemistry. 7th ed. New York: W. H. Freeman.
Keine Zertifikate für dieses Produkt in der Datenbank.
📚 Wissenschaftliche Referenzen (Chicago Author-Date) — zum Aufklappen klicken
Standards für Chargenmanagement und Laborzertifizierung — 13 unabhängige Quellen (ICH Q1/Q3/Q6/Q7/Q10 + ISO 17025 + WHO TRS + 21 CFR 211 + EMA + USP + Ph.Eur. + PIC/S + IPEC-PQG).
International Council for Harmonisation (ICH). 2000. "Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients." ICH Expert Working Group. [Link ↗] — GMP for APIs — adopted by EMA, FDA, MHLW
International Organization for Standardization. 2017. "ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories." ISO. [Link ↗] — Lab accreditation standard underpinning every CoA
World Health Organization. 2010. "WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles (WHO Technical Report Series No. 957, Annex 3)." WHO Press. [Link ↗] — WHO TRS No. 957 — global reference for GMP
International Council for Harmonisation (ICH). 2003. "ICH Q1A(R2): Stability Testing of New Drug Substances and Products." International Council for Harmonisation. [Link ↗] — Source for batch shelf-life and retest dating
International Council for Harmonisation (ICH). 2006. "ICH Q3A(R2): Impurities in New Drug Substances." ICH. [Link ↗]
International Council for Harmonisation (ICH). 1999. "ICH Q6A: Specifications for New Drug Substances and Products." ICH. [Link ↗] — CoA acceptance-criteria specification standard
International Council for Harmonisation (ICH). 2008. "ICH Q10: Pharmaceutical Quality System." ICH. [Link ↗]
U.S. Food and Drug Administration. 2024. "21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals." US Code of Federal Regulations. [Link ↗] — US legal mandate (Subpart J — Records and Reports)
European Medicines Agency. 2014. "Guideline on Process Validation for Finished Products — Information and Data to Be Provided EMA/CHMP/CVMP/QWP/BWP/70278/2012." European Medicines Agency. [Link ↗]
United States Pharmacopeial Convention. 2024. "United States Pharmacopeia and National Formulary, USP 47-NF 42." USP. [Link ↗]
European Pharmacopoeia Commission. 2024. "European Pharmacopoeia 11th Edition." Council of Europe — EDQM. [Link ↗]
Pharmaceutical Inspection Co-operation Scheme (PIC/S). 2021. "Guide to Good Manufacturing Practice for Medicinal Products PE 009-15." PIC/S Secretariat, Geneva. [Link ↗] — Cross-recognized GMP for 54 inspectorates worldwide
International Pharmaceutical Excipients Council (IPEC) and Pharmaceutical Quality Group (PQG). 2017. "Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients." IPEC-Americas. [Link ↗] — Excipient-grade CoA standard for non-API ingredients
Hedaya L, Naja K, Almuraikhy S et al.. (2025). "N-Lactoyl Phenylalanine Disrupts Insulin Signaling, Induces Inflammation, and Impairs Mitochondrial Respiration in Cell Models.". Cells. https://doi.org/10.3390/cells14161296 [DOI]
Wobst HJ, Viader A, Muncipinto G et al.. (2024). "SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.". JCI insight. https://doi.org/10.1172/jci.insight.182876 [DOI]
Václav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules26144298 [DOI]
Linstrom, Peter J., and William G. Mallard, eds. 2023. NIST Chemistry WebBook, NIST Standard Reference Database Number 69. Gaithersburg, MD: National Institute of Standards and Technology. [DOI]
Mayerhöfer, Thomas G., Samir Pahlow, and Jürgen Popp. 2020. "The Bouguer-Beer-Lambert Law: Shining Light on the Obscure." ChemPhysChem 21 (18): 2029-2046. [DOI]
Skoog, Douglas A., F. James Holler, and Stanley R. Crouch. 2017. Principles of Instrumental Analysis. 7th ed. Boston: Cengage Learning. ISBN 978-1-305-57721-3.
Lindon, John C., George E. Tranter, and David W. Koppenaal, eds. 2017. "Encyclopedia of Spectroscopy and Spectrometry." 3rd ed. Amsterdam: Academic Press. ISBN 978-0-12-803224-4.
Field, Leslie D., Sev Sternhell, and John R. Kalman. 2013. "Organic Structures from Spectra." 5th ed. Chichester: Wiley. ISBN 978-1-119-96582-6.
Reusch, William. 2013. "Virtual Textbook of Organic Chemistry: Spectroscopy." East Lansing, MI: Michigan State University.
Lampman, Gary M., Donald L. Pavia, George S. Kriz, and James R. Vyvyan. 2010. "Spectroscopy." 4th ed. Belmont, CA: Cengage Learning. ISBN 978-0-495-88992-9.
Kalsi, P. S. 2010. "Spectroscopy of Organic Compounds." 6th ed. New Delhi: New Age International. ISBN 978-81-224-2032-9.
Williams, Dudley H., and Ian Fleming. 2008. "Spectroscopic Methods in Organic Chemistry." 6th ed. London: McGraw-Hill. ISBN 978-0-07-711559-0.
Sadek, Paul C. 2002. The HPLC Solvent Guide. 2nd ed. Hoboken: Wiley. ISBN 978-0-471-41242-2.
Banwell, Colin N., and Elaine M. McCash. 1994. "Fundamentals of Molecular Spectroscopy." 4th ed. London: McGraw-Hill. ISBN 978-0-07-707976-1.
Perkampus, Heinz-Helmut. 1992. UV-VIS Spectroscopy and Its Applications. Berlin: Springer. https://doi.org/10.1007/978-3-642-77479-9.
Fieser, Louis F. 1949. "Extension of Woodward's Rules for Prediction of Conjugated Diene Absorption." Journal of the American Chemical Society 71 (5): 1854-1857. [DOI]
Woodward, Robert B. 1942. "Structure and the Absorption Spectra of Alpha,Beta-Unsaturated Ketones." Journal of the American Chemical Society 64 (1): 72-75. [DOI]
Beer, August. 1852. "Bestimmung der Absorption des rothen Lichts in farbigen Flüssigkeiten." Annalen der Physik und Chemie 86: 78-88. https://doi.org/10.1002/andp.18521620505.
Lambert, Johann Heinrich. 1760. Photometria. Augsburg: Sumptibus Vidae.
📖 The λmax = 257 nm value comes from a database/literature. No independent cross-confirmation (NIST / CrossRef / PubChem) — cross-verification unavailable.
📜 Patente (öffentliche Metadaten)
keine Daten MolGod_PATENT_2
Derzeit wurden keine öffentlichen Patent-Metadaten für diese Substanz in Crossref / OpenAlex gefunden. Die Daten werden nach der nächsten Cache-Aktualisierung automatisch ergänzt (24h).
📚 Referenzen (Chicago Author-Date) — zum Aufklappen klicken
Hedaya L, Naja K, Almuraikhy S et al.. (2025). "N-Lactoyl Phenylalanine Disrupts Insulin Signaling, Induces Inflammation, and Impairs Mitochondrial Respiration in Cell Models.". Cells. https://doi.org/10.3390/cells14161296
Wobst HJ, Viader A, Muncipinto G et al.. (2024). "SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.". JCI insight. https://doi.org/10.1172/jci.insight.182876
Václav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules26144298
World Intellectual Property Organization. 2024. "Patent Cooperation Treaty (PCT)." https://www.wipo.int/pct/.
U.S. Patent and Trademark Office. 2024. "USPTO Patent Public Search." https://ppubs.uspto.gov/.
European Patent Office. 2024. "Espacenet Patent Search." https://worldwide.espacenet.com/.
Newman, David J., and Gordon M. Cragg. 2020. "Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019." Journal of Natural Products 83 (3): 770-803.
Davies, Mark, Michał Nowotka, George Papadatos, et al. 2015. "ChEMBL Web Services: Streamlining Access to Drug Discovery Data and Utilities." Nucleic Acids Research 43 (W1): W612-W620.
Bickerton, G. Richard, Gaia V. Paolini, Jérémy Besnard, Sorel Muresan, and Andrew L. Hopkins. 2012. "Quantifying the Chemical Beauty of Drugs." Nature Chemistry 4 (2): 90-98.
Meanwell, Nicholas A. 2011. "Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design." Journal of Medicinal Chemistry 54 (8): 2529-2591.
Ertl, Peter, and Ansgar Schuffenhauer. 2009. "Estimation of Synthetic Accessibility Score of Drug-Like Molecules Based on Molecular Complexity and Fragment Contributions." Journal of Cheminformatics 1: 8.
Hopkins, Andrew L., and Colin R. Groom. 2002. "The Druggable Genome." Nature Reviews Drug Discovery 1 (9): 727-730.
Allison, John R., and Mark A. Lemley. 1998. "Empirical Evidence on the Validity of Litigated Patents." AIPLA Quarterly Journal 26 (3): 185-275.
Patani, George A., and Edmond J. LaVoie. 1996. "Bioisosterism: A Rational Approach in Drug Design." Chemical Reviews 96 (8): 3147-3176.
Lerner, Josh. 1994. "The Importance of Patent Scope: An Empirical Analysis." RAND Journal of Economics 25 (2): 319-333.
Stereochemistry, specific rotation and recommended chiral HPLC column for CAS 63-91-2 (CIP per Cahn-Ingold-Prelog 1966).
Vorhersagedaten — CIP-Konfiguration aus der SMILES-Struktur abgeleitet. Spezifische Drehung und Säulenauswahl sind Schätzwerte. Vor der analytischen Anwendung mit ChemSpider/PubChem und einem CD-Spektrum verifizieren.
Centra stereogeniczne
1
Konfiguracja
(S) — konfiguracja absolutna (CIP)
Specific rotation [α]D20
-35.00°
(−) levorotatory • solv.: H2O • c=1.5, 25°C
Enancjomer (para)
CAS 673-06-3
Rekomendowana kolumna HPLC
Crownpak CR(+)
Faza ruchoma (eluent)
HClO4(aq) pH 1.5
Bibliografie (Chicago Author-Date)
Eliel, Ernest L., Samuel H. Wilen, and Lewis N. Mander. 1994. "Stereochemistry of Organic Compounds." New York: Wiley.
Cahn, Robert S., Christopher Ingold, and Vladimir Prelog. 1966. "Specification of Molecular Chirality." Angewandte Chemie International Edition 5 (4): 385-415. https://doi.org/10.1002/anie.196603851.
Francotte, Eric, and Wolfgang Lindner, eds. 2006. "Chirality in Drug Research." Weinheim: Wiley-VCH.
U.S. FDA. 1992. "FDA's Policy Statement for the Development of New Stereoisomeric Drugs." Chirality 4 (5): 338-340. https://doi.org/10.1002/chir.530040513.
Patani, George A., and Edmond J. LaVoie. 1996. "Bioisosterism: A Rational Approach in Drug Design." Chemical Reviews 96 (8): 3147-3176.
Meanwell, Nicholas A. 2011. "Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design." Journal of Medicinal Chemistry 54 (8): 2529-2591.
Davies, Mark, Michał Nowotka, George Papadatos, et al. 2015. "ChEMBL Web Services: Streamlining Access to Drug Discovery Data and Utilities." Nucleic Acids Research 43 (W1): W612-W620.
Easson, Leslie H., and Edgar Stedman. 1933. "Studies on the relationship between chemical constitution and physiological action: molecular dissymmetry and physiological activity." Biochemical Journal 27 (4): 1257-1266. https://doi.org/10.1042/bj0271257.
Pirkle, William H., and Thomas C. Pochapsky. 1989. "Considerations of chiral recognition relevant to the liquid chromatography separation of enantiomers." Chemical Reviews 89 (2): 347-362. https://doi.org/10.1021/cr00092a006.
Dale, James A., and Harry S. Mosher. 1973. "Nuclear magnetic resonance enantiomer reagents: configurational correlations via nuclear magnetic resonance chemical shifts of diastereomeric mandelate, O-methylmandelate, and α-methoxy-α-trifluoromethylphenylacetate (MTPA) esters." Journal of the American Chemical Society 95 (2): 512-519. https://doi.org/10.1021/ja00783a034.
Beesley, Thomas E., and Raymond P. W. Scott. 1998. Chiral Chromatography. Chichester: John Wiley & Sons.
Allenmark, Stig G. 1991. Chromatographic Enantioseparation: Methods and Applications. 2nd ed. New York: Ellis Horwood.
Wainer, Irving W., ed. 1993. Drug Stereochemistry: Analytical Methods and Pharmacology. 2nd ed. New York: Marcel Dekker.
Aboul-Enein, Hassan Y., and Irving W. Wainer, eds. 1997. The Impact of Stereochemistry on Drug Development and Use. New York: John Wiley & Sons.
Ahuja, Satinder, ed. 2000. Chiral Separations by Liquid Chromatography. ACS Symposium Series 471. Washington, DC: American Chemical Society.
Maier, Norbert M., Pilar Franco, and Wolfgang Lindner. 2001. "Separation of enantiomers: needs, challenges, perspectives." Journal of Chromatography A 906 (1-2): 3-33. https://doi.org/10.1016/S0021-9673(00)00532-X.
Schurig, Volker. 2001. "Separation of enantiomers by gas chromatography." Journal of Chromatography A 906 (1-2): 275-299. https://doi.org/10.1016/S0021-9673(00)00505-7.
Okamoto, Yoshio, and Eiji Yashima. 1998. "Polysaccharide derivatives for chromatographic separation of enantiomers." Angewandte Chemie International Edition 37 (8): 1020-1043. https://doi.org/10.1002/(SICI)1521-3773(19980504)37:8<1020::AID-ANIE1020>3.0.CO;2-5.
Lämmerhofer, Michael. 2010. "Chiral recognition by enantioselective liquid chromatography: mechanisms and modern chiral stationary phases." Journal of Chromatography A 1217 (6): 814-856. https://doi.org/10.1016/j.chroma.2009.10.022.
Caner, Hava, Eli Groner, Liron Levy, and Israel Agranat. 2004. "Trends in the development of chiral drugs." Drug Discovery Today 9 (3): 105-110. https://doi.org/10.1016/S1359-6446(03)02904-0.
Agranat, Israel, Hava Caner, and John Caldwell. 2002. "Putting chirality to work: the strategy of chiral switches." Nature Reviews Drug Discovery 1 (10): 753-768. https://doi.org/10.1038/nrd915.
Crosby, John. 1991. "Synthesis of optically active compounds: a large-scale perspective." Tetrahedron 47 (27): 4789-4846. https://doi.org/10.1016/S0040-4020(01)80950-6.
Nguyen, Lien Ai, Hua He, and Chuong Pham-Huy. 2006. "Chiral drugs: an overview." International Journal of Biomedical Science 2 (2): 85-100.
Eriksson, Tommy, Sven Björkman, and Peter Höglund. 2001. "Clinical pharmacology of thalidomide." European Journal of Clinical Pharmacology 57 (5): 365-376. https://doi.org/10.1007/s002280100320.
Evans, Andrew M. 2007. "Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen." Clinical Rheumatology 20 (Suppl 1): S9-S14. https://doi.org/10.1007/BF03342661.
IUPAC. 1996. "Basic terminology of stereochemistry (IUPAC recommendations 1996)." Pure and Applied Chemistry 68 (12): 2193-2222. https://doi.org/10.1351/pac199668122193.
Mislow, Kurt, and Jay Siegel. 1984. "Stereoisomerism and local chirality." Journal of the American Chemical Society 106 (11): 3319-3328. https://doi.org/10.1021/ja00323a043.
Francotte, Eric R. 2001. "Enantioselective chromatography as a powerful alternative for the preparation of drug enantiomers." Journal of Chromatography A 906 (1-2): 379-397. https://doi.org/10.1016/S0021-9673(00)00951-1.
Welch, Christopher J. 1994. "Evolution of chiral stationary phase design in the Pirkle laboratories." Journal of Chromatography A 666 (1-2): 3-26. https://doi.org/10.1016/0021-9673(94)80367-6.
Armstrong, Daniel W., Yibing Tang, Shengsheng Chen, et al. 1994. "Macrocyclic antibiotics as a new class of chiral selectors for liquid chromatography." Analytical Chemistry 66 (9): 1473-1484. https://doi.org/10.1021/ac00081a019.
Pirkle, William H., Donn W. House, and Jerald M. Finn. 1980. "Broad spectrum resolution of optical isomers using chiral high-performance liquid chromatographic bonded phases." Journal of Chromatography A 192 (1): 143-158. https://doi.org/10.1016/S0021-9673(80)80043-3.
European Directorate for the Quality of Medicines & HealthCare. 2024. European Pharmacopoeia 11.5: Chapter 2.2.7 Optical rotation. Strasbourg: EDQM Council of Europe.
United States Pharmacopeial Convention. 2024. USP-NF General Chapter <781> Optical Rotation. Rockville, MD: USP.
Gal, Joseph. 2017. "Pasteur and the art of chirality." Nature Chemistry 9 (7): 604-605. https://doi.org/10.1038/nchem.2790.
Pasteur, Louis. 1848. "Mémoire sur la relation qui peut exister entre la forme cristalline et la composition chimique, et sur la cause de la polarisation rotatoire." Comptes rendus de l'Académie des sciences 26: 535-538.
Le Bel, Joseph A. 1874. "Sur les relations qui existent entre les formules atomiques des corps organiques et le pouvoir rotatoire de leurs dissolutions." Bulletin de la Société Chimique de France 22: 337-347.
van 't Hoff, Jacobus Henricus. 1874. "Voorstel tot uitbreiding der tegenwoordige in de scheikunde gebruikte structuur-formules in de ruimte, benevens een daarmede samenhangende opmerking omtrent het verband tusschen optisch actief vermogen en chemische constitutie van organische verbindingen." Utrecht: J. Greven.
PUBHedaya L, Naja K, Almuraikhy S et al.. (2025). "N-Lactoyl Phenylalanine Disrupts Insulin Signaling, Induces Inflammation, and Impairs Mitochondrial Respiration in Cell Models.". Cells. https://doi.org/10.3390/cells14161296
PUBWobst HJ, Viader A, Muncipinto G et al.. (2024). "SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.". JCI insight. https://doi.org/10.1172/jci.insight.182876
DOAVáclav Pokorný, Vojtěch Štejfa, Jakub Havlín et al.. (2021). "Heat Capacities of l-Histidine, l-Phenylalanine, l-Proline, l-Tryptophan and l-Tyrosine". Molecules. https://doi.org/10.3390/molecules26144298
Bibliografie (erweitert) (6)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertTanchai, Nipawan. "Improvement of the phenylalanine dehydrogenase immobilization method for the production of phenylalanine.". https://doi.org/10.58837/chula.the.2007.1012.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Self-Assembly of Phenylalanine-Leucine, Leucine-Phenylalanine and Cyclo(-leucine-phenylalanine) Dipeptides through Simulations and Experiments.". https://doi.org/10.1021/acs.jpcb.2c08576.s001.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine.". https://doi.org/10.31003/uspnf_m64020_04_01.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine Binding Is Linked to Dimerization of the Regulatory Domain of Phenylalanine Hydroxylase.". https://doi.org/10.1021/bi501109s.s001.Link[abgerufen: 2026-11-07]CC0 (metadata)
★★☆☆☆CROSSREF🔓 OFFEN❓ nicht verifiziertAnonymous. "Phenylalanine.". https://doi.org/10.31003/uspnf_m64020_05_01.Link[abgerufen: 2026-11-07]CC0 (metadata)
★☆☆☆☆OPENLIBRARY🔓 OFFENMaria Yeng-Ying Kuo. 1977. "A kinetic study of the carboxypeptidase A catalyzed hydrolyses of Cinnamoylglycyl-L-phenylalanine (CinGP) and Hydrocinnamoylglycyl-L-phenylalanine (HCinGP) / by Maria Yeng-Ying Kuo." Miami University.Link[abgerufen: 2026-11-03]CC0 (metadata)
Haben Sie einen Blog, ein Forum oder einen wissenschaftlichen Dienst? Betten Sie das interaktive 3D-Molekül auf Ihrer Website ein — jeder Ihrer Leser sieht es, und darunter gibt es einen Link zu unserem Shop, wo er das Reagenz kaufen kann.
📱 QR code (zum Druck auf Flyern / Etiketten / Katalogen)
Platzieren Sie ihn in einem Produktkatalog, auf einem Flaschenetikett oder einem Flyer. Der Kunde scannt ihn — sieht das 3D-Molekül auf seinem Telefon, mit einem Link zu Ihrem Shop.
Wenn Sie den Link teilen, ruft Facebook/LinkedIn/Discord automatisch die Bildvorschau ab:
📋 Lizenz: Der Embed behält einen Backlink zu Eapearl Chemical (erforderlich — der Shop ist die Datenquelle). Chemische Daten stammen von PubChem (CC0 — gemeinfrei). Der Embed ist KOSTENLOS für Bildungs-, kommerzielle und Hobbyzwecke.
📚 REFERENZEN (Gesammelte Bibliografie, Chicago Author-Date) 120 Einträge
Alle wissenschaftlichen Quellen, die in den Akkordeons oben für CAS 63-91-2 zitiert werden.Format: Chicago Manual of Style, 17. Aufl., Autor-Datum-System.
🗄️ Wissenschaftliche Datenbanken
PubChem. n.d. PubChem Compound Summary: CAS 63-91-2. Bethesda, MD: National Center for Biotechnology Information (NCBI), National Library of Medicine.
AIST. n.d. Spectral Database for Organic Compounds (SDBS): CAS 63-91-2. Tsukuba, Japan: National Institute of Advanced Industrial Science and Technology. https://sdbs.db.aist.go.jp/.
Linstrom, Peter J., and William G. Mallard, eds. n.d. NIST Chemistry WebBook: NIST Standard Reference Database Number 69. Gaithersburg, MD: National Institute of Standards and Technology. https://doi.org/10.18434/T4D303.
European Chemicals Agency (ECHA). 2024. "Annex VI to Regulation (EC) No 1272/2008 (CLP) — Harmonised Classification and Labelling." ECHA, Helsinki / Official Journal of the European Union. https://echa.europa.eu/regulations/clp/clp-classification.
National Institute for Occupational Safety and Health (NIOSH). 2017. "Recommendations for Chemical Protective Clothing: A Companion to the NIOSH Pocket Guide." U.S. Department of Health & Human Services / CDC. https://www.cdc.gov/niosh/ncpc/default.html.
Connors, Kenneth A., Gordon L. Amidon, and Valentino J. Stella. 1986. Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, 2nd ed.. New York: Wiley. https://doi.org/10.1002/0471734683.
Rumble, John R., ed. 2019. CRC Handbook of Chemistry and Physics: 100th Edition. Boca Raton, FL: CRC Press. https://hbcp.chemnetbase.com/.
Stefanis, Emmanuel, and Costas Panayiotou. 2008. "Prediction of Hansen Solubility Parameters with a New Group-Contribution Method." International Journal of Thermophysics 29: 568-585. https://doi.org/10.1007/s10765-008-0415-z.
Stoll, Vincent S., and John S. Blanchard. 1990. "Buffers: Principles and Practice: In Methods in Enzymology, vol. 182." San Diego: Academic Press. https://doi.org/10.1016/0076-6879(90)82008-P.
European Parliament. 2008. "Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures (CLP)." Official Journal of the European Union L 353: 1–1355.
United Nations. 2021. Globally Harmonized System of Classification and Labelling of Chemicals (GHS). 9th revised ed. ST/SG/AC.10/30/Rev.9. New York and Geneva: United Nations. https://unece.org/ghs-rev9-2021.
Snyder, Lloyd R., John W. Dolan, and Joseph J. Kirkland. 2010. Introduction to Modern Liquid Chromatography. Wiley.
Schoenmakers, Peter J.. 1986. Optimization of Chromatographic Selectivity: A Guide to Method Development. Elsevier.
Snyder, L. R., and J. W. Dolan. 2007. High-Performance Gradient Elution: The Practical Application of the Linear-Solvent-Strength Model. Wiley.
Nikitas, Pavlos, and Adrian Pappa-Louisi. 2009. "Retention models for isocratic and gradient elution in reversed-phase liquid chromatography." Journal of Chromatography A 1216: 1737-1755. https://doi.org/10.1016/j.chroma.2008.10.005.
Wu, Naijun, and Anton M. Clausen. 2007. "Fundamental and practical aspects of ultrahigh pressure liquid chromatography for fast separations." Journal of Separation Science 30: 1167-1182. https://doi.org/10.1002/jssc.200700026.
Stoll, Dwight R., and Peter W. Carr. 2017. "Two-Dimensional Liquid Chromatography: A State of the Art Tutorial." Analytical Chemistry 89: 519-531. https://doi.org/10.1021/acs.analchem.6b03506.
Van Deemter, J. J., F. J. Zuiderweg, and A. Klinkenberg. 1956. "Longitudinal diffusion and resistance to mass transfer as causes of nonideality in chromatography." https://doi.org/10.1016/0009-2509(56)80003-1.
Giddings, J. Calvin. 1965. "Dynamics of Chromatography, Part I: Principles and Theory." Marcel Dekker.
Wu, Naijun, and Anton M. Clausen. 2007. "Fundamental and practical aspects of ultrahigh pressure liquid chromatography for fast separations." https://doi.org/10.1002/jssc.200700026.
Foley, Joe P., and John G. Dorsey. 1983. "Equations for calculation of chromatographic figures of merit for ideal and skewed peaks." https://doi.org/10.1021/ac00255a033.
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. "Introduction to Modern Liquid Chromatography." Wiley. https://doi.org/10.1002/9780470508183.
Vivó-Truyols, Gabriel, and Hans-Gerd Janssen. 2010. "Probabilistic approach to peak deconvolution in chromatography." https://doi.org/10.1021/ac101742z.
Kromidas, Stavros. 2017. "HPLC Made to Measure: A Practical Handbook for Optimization." Wiley-VCH.
United States Pharmacopeial Convention. 2024. "USP <621> Chromatography." In United States Pharmacopeia and National Formulary, USP 47-NF 42. Rockville, MD: USP. https://www.uspnf.com/.
International Organization for Standardization. 2017. "ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories." Geneva: ISO. https://www.iso.org/standard/66912.html.
Kolthoff, Izaak Maurits, and Philip J. Elving, eds. 1978. Treatise on Analytical Chemistry, Part I: Theory and Practice. 2nd ed. New York: Wiley-Interscience.
Skoog, Douglas A., F. James Holler, and Stanley R. Crouch. 2018. Principles of Instrumental Analysis. 7th ed. Boston: Cengage Learning.
Christian, Gary D., Purnendu K. Dasgupta, and Kevin A. Schug. 2014. Analytical Chemistry. 7th ed. Hoboken, NJ: Wiley.
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. "Introduction to Modern Liquid Chromatography." John Wiley & Sons. https://doi.org/10.1002/9780470508183.
US Food and Drug Administration (FDA). 2018. "Reviewer Guidance: Validation of Chromatographic Methods." US Food and Drug Administration. https://www.fda.gov/media/74954/download.
International Organization for Standardization. 1994. "ISO 5725-2:1994 Accuracy (Trueness and Precision) of Measurement Methods and Results — Part 2: Basic Method for the Determination of Repeatability and Reproducibility of a Standard Measurement Method." Geneva: ISO. https://www.iso.org/standard/11834.html.
Heckert, N. A., and J. J. Filliben. 2003. "NIST/SEMATECH e-Handbook of Statistical Methods." NIST Handbook 151. Gaithersburg, MD: National Institute of Standards and Technology. https://www.itl.nist.gov/div898/handbook/.
Grubbs, Frank E. 1950. "Sample Criteria for Testing Outlying Observations." Annals of Mathematical Statistics 21 (1): 27–58.
Dixon, Wilfrid J. 1950. "Analysis of Extreme Values." Annals of Mathematical Statistics 21 (4): 488–506.
Snedecor, George W., and William G. Cochran. 1989. Statistical Methods. 8th ed. Ames, IA: Iowa State University Press.
Student [William Sealy Gosset]. 1908. "The Probable Error of a Mean." Biometrika 6 (1): 1–25.
International Organization for Standardization. 2005. "ISO 3534-1:2006 Statistics — Vocabulary and Symbols — Part 1: General Statistical Terms and Terms Used in Probability." Geneva: ISO. https://www.iso.org/standard/40145.html.
Thompson, Michael, Stephen L. R. Ellison, and Roger Wood. 2002. "Harmonized Guidelines for Single-Laboratory Validation of Methods of Analysis." Pure and Applied Chemistry 74 (5): 835–855.
United Nations Economic Commission for Europe. 2024. European Agreement Concerning the International Carriage of Dangerous Goods by Road (ADR), Applicable as from 1 January 2025 (ECE/TRANS/352). Geneva: UNECE. https://unece.org/transport/dangerous-goods/adr-2025-edition.
Ministry of Climate and Environment of the Republic of Poland. 2020. "Regulation of the Minister of Climate of 2 January 2020 on the waste catalogue." Journal of Laws of the Republic of Poland 2020 item 10. https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20200000010.
Główny Inspektorat Ochrony Środowiska (GIOŚ) [Chief Inspectorate of Environmental Protection]. 2024. "Baza Danych O Odpadach (BDO) — Waste disposal company registration system." Ministry of Climate and Environment. https://bdo.mos.gov.pl/.
International Organization for Standardization. 2017. "ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories." ISO. https://www.iso.org/standard/66912.html.
World Health Organization. 2010. "WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles (WHO Technical Report Series No. 957, Annex 3)." WHO Press. https://www.who.int/publications/m/item/trs957-annex3.
Pharmaceutical Inspection Co-operation Scheme (PIC/S). 2021. "Guide to Good Manufacturing Practice for Medicinal Products PE 009-15." PIC/S Secretariat, Geneva. https://picscheme.org/en/publications.
